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Physiology And The Hemostatic Response 
Abstract 
G protein-coupled receptors (GPCRs) are critical mediators of platelet activation whose signaling is 
limited in part by members of the regulator of G protein signaling (RGS) family. To better understand how 
individual RGS proteins impact the optimal balance between activation and inhibition, the most abundant 
RGS in platelets, RGS10 and RGS18, were deleted both individually and simultaneously in mice. Loss of 
RGS10 causes increased platelet activation and accumulation following hemostatic injury, due to an 
expansion of the P-selectin(─) shell, driven by thromboxane A2 and ADP, rather than the P-selectin(+) core, 
driven by thrombin. Loss of RGS18 results in milder increases in GPCR signaling, primarily thrombin-
dependent, and causes moderate thrombocytopenia, due to decreased platelet production. Loss of both 
RGS10 and RGS18 results in dramatically increased platelet activation and accumulation in vivo, with an 
expansion of both the P-selectin(+) core and the P-selectin(─) shell, and uninhibited growth that increases 
the occurrence of vascular occlusion. Furthermore, dual deletion of RGS10 and RGS18 results in reduced 
platelet survival due to premature activation in circulation and subsequent clearance. Additionally, in 
efforts to explore RGS-mediated regulation of Gq signaling in platelets, we induced a homozygous RGS-
insensitive G188S mutation in mouse Gq(alpha) [Gq(alpha) G188S]. Unexpectedly, Gq(alpha) G188S mice 
had dramatically reduced platelet accumulation in vivo, which was due to decreased Gq signaling via 
disrupted PLC(beta) interactions. Structural and computational analyses revealed substantial overlap 
between RGS and effector binding interfaces, but provided candidate mutations predicted to specifically 
disrupt RGS interactions. Finally, to corroborate our results with mouse models, we sought to identify 
predicted loss-of-function RGS10 and RGS18 variants in human patients and analyze their platelet 
function. We identified 16 variants in 101 patients and have plans to recall them to analyze platelet 
reactivity and RGS expression levels. Viable candidates will also be selected for in vivo hemostatic 
analysis using iPSC-derived megakaryocytes and a humanized mouse model. Overall, these studies 
demonstrate how RGS-mediated regulation of platelet GPCRs is important for platelet production, survival 
and hemostatic reactivity. Furthermore, it suggests that a delicate equilibrium between negative and 
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REGULATORS OF G PROTEIN SIGNALING MODULATE PLATELET FUNCTION TO IMPACT 
NORMAL PHYSIOLOGY AND THE HEMOSTATIC RESPONSE 
Daniel John DeHelian 
Lawrence “Skip” F. Brass, MD PhD 
G protein-coupled receptors (GPCRs) are critical mediators of platelet activation whose signaling 
is limited in part by members of the regulator of G protein signaling (RGS) family. To better 
understand how individual RGS proteins impact the optimal balance between activation and 
inhibition, the most abundant RGS in platelets, RGS10 and RGS18, were deleted both individually 
and simultaneously in mice. Loss of RGS10 causes increased platelet activation and accumulation 
following hemostatic injury, due to an expansion of the P-selectin(─) shell, driven by thromboxane 
A2 and ADP, rather than the P-selectin(+) core, driven by thrombin. Loss of RGS18 results in milder 
increases in GPCR signaling, primarily thrombin-dependent, and causes moderate 
thrombocytopenia, due to decreased platelet production. Loss of both RGS10 and RGS18 results 
in dramatically increased platelet activation and accumulation in vivo, with an expansion of both 
the P-selectin(+) core and the P-selectin(─) shell, and uninhibited growth that increases the 
occurrence of vascular occlusion. Furthermore, dual deletion of RGS10 and RGS18 results in 
reduced platelet survival due to premature activation in circulation and subsequent clearance. 
Additionally, in efforts to explore RGS-mediated regulation of Gq signaling in platelets, we induced 
a homozygous RGS-insensitive G188S mutation in mouse Gq (Gq G188S). Unexpectedly, Gq 
G188S mice had dramatically reduced platelet accumulation in vivo, which was due to decreased 
Gq signaling via disrupted PLC interactions Structural and computational analyses revealed 
substantial overlap between RGS and effector binding interfaces, but provided candidate mutations 
predicted to specifically disrupt RGS interactions. Finally, to corroborate our results with mouse 
models, we sought to identify predicted loss-of-function RGS10 and RGS18 variants in human 
patients and analyze their platelet function. We identified 16 variants in 101 patients and have plans 
to recall them to analyze platelet reactivity and RGS expression levels. Viable candidates will also 
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be selected for in vivo hemostatic analysis using iPSC-derived megakaryocytes and a humanized 
mouse model. Overall, these studies demonstrate how RGS-mediated regulation of platelet 
GPCRs is important for platelet production, survival and hemostatic reactivity. Furthermore, it 
suggests that a delicate equilibrium between negative and positive platelet activation regulators is 
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CHAPTER 1: Regulation of Platelet Activation 
 1.1 Platelets in Hemostasis and Thrombosis 
Under normal conditions, the blood vessel endothelium maintains platelets in an inactive 
state by 1) physically separating them from subendothelial collagen and tissue factor (TF), 2) 
expressing CD39, a surface ecto-apyrase, and 3) producing nitric oxide (NO) and prostaglandin I2 
(PGI2) (Figure 1-1A) 1-3. If the endothelium is injured, however, a rapid response to stem bleeding 
and reduce blood loss (known as hemostasis) is triggered. The initial phase of this process involves 
adhesion of platelets to the subendothelial matrix and initiation of the coagulation cascade (Figure 
1-1B). Initial platelet interactions via transmembrane receptors induce intracellular signaling 
cascades that ultimately result in platelet activation.4 Platelet activation stimulates aggregation via 
inside-out activation of surface integrins, in particular IIb3, thus increasing affinity for extracellular 
substrates to mediate platelet-platelet adhesion.5 Furthermore, activated platelets release 
secondary agonists, such as TxA2 and ADP, to activate additionally recruited platelets (Figure 1-
1C).6 Simultaneously, the coagulation cascade, initiated when circulating factors encounter tissue 
factor in the adventitia, generates thrombin, which has two major roles in hemostasis: 1) further 
activation of platelets by cleaving surface receptors7 and 2) conversion of soluble fibrinogen to 
insoluble fibrin, which is then polymerized into networks that help stabilize the growing clot (Figure 
1-1C)8. Defects in either the coagulation cascade (such as hemophilia)9 or platelet 
adhesion/aggregation (such as Glanzmann’s thrombasthenia)10 can result in a bleeding diathesis, 
highlighting the importance of these interrelated phenomena to hemostasis. 
In contrast, conditions such as cardiovascular disease (CVD) can create an environment 
that favors unwarranted platelet activation and excessive clot growth, known as thrombosis.11 
Under these circumstances, particularly in arterial thrombosis, rupture of TF-rich atherosclerotic 
plaques can result in excessive thrombin production and occlusive platelet-rich clot formation 
(Figure 1-1D)12. Complications (such as myocardial infarction or stroke) arising from CVD are the 





Figure 1-1. Platelet activation under physiological and pathological settings. 
(A) Under normal conditions, the endothelium provides several mechanisms (red) to 
prevent platelet activation. (B) Upon injury to the endothelium, (1) platelets begin adhering 
to the subendothelial matrix and undergoing activation, and (2) the coagulation cascade, 
mediated by exposure of tissue factor, begins generating thrombin (C) Activated platelets 
at the site of injury release secondary signaling agonists ADP and TxA2. Additionally, 
thrombin plays dual roles by further activating platelets and converting soluble fibrinogen 
to insoluble fibrin, that then polymerizes into a network to stabilize the growing clot. (D) In 
contrast, atherosclerotic plaque rupture and aberrant thrombin generation can result in 
excessive platelet activation such that the clot blocks blood flow in the vessel, which results 






 1.2 Positive and Negative Regulation of Platelet Activation 
“Platelet activation” is a term used to describe the morphological and biochemical 
transformations that a platelet undergoes during a hemostatic response to injury or the pathological 
response to an insult such as atherosclerotic plaque rupture. These transformations include 
cytoskeletal rearrangements (that result in shape change, from a discoid to spherical shape), 
exocytosis of dense and  granules (that release markers of platelet activation, such as P-selectin, 
and secondary mediators of platelet activation, such as ADP, respectively), production of TxA2 
(another secondary mediator of platelet activation), and inside-out activation of integrin IIb3 (that 
forms platelet-platelet contacts via fibrinogen).6 Platelet activation is mediated, in large part, by the 
transduction of extracellular signals through transmembrane receptors. 
GPVI, an immunoglobulin superfamily receptor, is stimulated by binding to collagen in the 
subendothelial matrix. It is constitutively associated with the immunoreceptor tyrosine-activating 
motif (ITAM)-containing Fc receptor -chain (FcR).14 Upon binding to collagen, Src family tyrosine 
kinases, Lyn and Fyn, constitutively associated with the proline-rich domain in GPVI, phosphorylate 
tyrosine residues within consensus ITAM sequences in FcR.15 Once phosphorylated, these 
consensus sequences serve as recruitment sites for the SH2 domains of Syk, another tyrosine 
kinase. Bound Syk becomes activated, initiating a phosphorylation cascade that results in formation 
of the linker of activated T cells (LAT) signalosome and activation of phospholipase C (PLC) 
 (Figure 1-2).15 PLC cleaves phosphatidylinositol 4,5-bisphosphate (PIP2) into diacyl glycerol 
(DAG) and inositol 1,4,5-trisphosphate (IP3). DAG is an important activator of conventional and 
novel isoforms of protein kinase C (PKC) while IP3 stimulates the release of intracellular Ca2+ from 
stores in the dense tubular system (Figure 1-2).16 Finally, PKCs (primarily conventional isoforms) 
phosphorylate downstream effectors involved in platelet activation,17 while intracellular Ca2+ acts 
as a potent secondary messenger.18 Together, these mechanisms combine to initiate activation-




The G protein-coupled receptor (GPCR) superfamily is involved in both platelet activation 
and inhibition. As the name implies, each GPCR is coupled to a heterotrimeric complex of G 
proteins composed of , , and  subunits and can be subdivided into one of four families: Gs, Gi, 
Gq, and G12, based upon the characteristics of their coupled  subunit. At rest, the  subunit of the 
complex is bound to GDP and its effector-binding interface is occupied by the tightly associated 
 dimer (Figure 1-3A). Upon agonist stimulation of the coupled GPCR, the  subunit releases GDP 
and it is rapidly replaced with more abundant GTP.19 In this GTP-bound state, the  subunit 
dissociates from the  dimer, allowing both to bind to downstream effectors (Figure 1-3B). The 
diverse functions of individual GPCRs and their downstream effects are dependent upon the nature 
of the individual subunits within the associated heterotrimeric complex.20 
Three of the four major GPCR families, Gi, Gq, and G12, are involved in platelet activation. 
The platelet P2Y12 receptor, activated by its agonist adenosine diphosphate (ADP), is the 
predominant Gi-coupled family member in platelets, and has a major role in relieving inhibitory 
pathways. It couples to Gi2, which antagonizes the effects of Gs by inhibiting adenylyl cyclase (AC) 
to promote platelet activation (Figure 1-2). Furthermore, its associated  subunits stimulate 
phosphoinositide-3-kinase (PI3K), which inhibits RASA3, a GTPase activating protein (GAP) for 
the small GTPase RAP1. As RAP1 is only active in its GTP-bound form, inhibiting its GAP promotes 
integrin IIb3 activation and platelet aggregation.21 
Multiple platelet GPCRs couple to Gq subunits, including the protease activated receptors 
(PARs), the thromboxane A2 (TxA2) receptor (TP), and the ADP-activated P2Y1 receptor. Activated 
Gq stimulates  isoforms of phospholipase C (PLC), which in turn generates DAG and IP3 by 
cleaving PIP2.22 At this point, GPVI and Gq-coupled GPCR signaling pathways converge, and the 
resulting downstream signaling effects of these secondary molecules are virtually indistinguishable, 
activating PKCs and stimulating the release of intracellular Ca2+, respectively (Figure 1-2). 
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The predominant G12 isoform in platelets, G13, couples to both PARs and TP receptors. 
Activated G13 stimulates guanine nucleotide exchange factors (GEFs), including p115RhoGEF, 
that in turn leads to the exchange of GDP for GTP on the small GTPase, Rho (Figure 1-2).23 GTP-
bound Rho activates p160ROCK, a Rho-dependent kinase, which phosphorylates downstream 
effectors that mediate reorganization of the actin cytoskeleton.24 
In addition, to those transmembrane receptors that promote platelet activation, there are 
also numerous mechanisms that restrain activation. The prostaglandin I2 (PGI2) receptor (IP) 
represents the predominant Gs-coupled GPCR present in platelets. The active s subunit binds to 
and activates AC, which converts adenosine triphosphate (ATP) to cyclic adenosine 
monophosphate (cAMP). cAMP, in turn, binds to and activates protein kinase A (PKA), a 
serine/threonine kinase that phosphorylates multiple substrates. The net effect of this signaling 
cascade is inhibition of platelet activation (Figure 1-2).25 Similarly, NO produced by endothelial cells 
can directly bypass the platelet membrane to activate soluble guanylyl cyclase (sGC), produce 
cyclic guanosine monophosphate (cGMP), and stimulate protein kinase G (PKG), another 
serine/threonine kinase involved in inhibition of platelet activation signaling pathways.26 Finally, the 
endothelial ecto-apyrase, CD39, converts ATP and ADP in the circulation to AMP.1 As ADP 
stimulates platelet activating Gq-coupled P2Y1 and Gi2-coupled P2Y12 receptors, CD39 limits 
unnecessary signaling and aberrant activation under basal conditions. 
The presence of such a variety of mechanisms that both promote and restrain platelet 
signaling networks suggests the importance of maintaining a delicate balance between activation 
and inhibition. Moreover, it implies potential redundancy if a pathway were to be rendered 
inoperable. Of particular interest to our lab are the regulators of G protein signaling (RGS), negative 





  Figure 1-2. Signal transduction and platelet activation. Overview of signal 
transduction mechanisms that promote or inhibit platelet activation. Endogenous agonists 
are labelled above each G protein-coupled receptor with the receptor name in parentheses. 
Black indicates activating while red indicates inhibitory pathways. AC, adenylyl cyclase; 
ATP, adenosine triphosphate; [Ca++]i, intracellular cytosolic calcium; cAMP, cyclic 
adenosine monophosphate; GTP, guanosine 5’-triphosphate; PI3K, phosphatidylinositol 3-




1.3 Regulators of G protein Signaling 
 The magnitude of a GPCR-mediated response is proportional, at least in part, to the 
duration of the signaling via GTP-bound G and, in some cases, unbound . G possesses 
intrinsic GTPase activity with which it can hydrolyze the terminal phosphate of GTP to generate 
GDP, resulting in reassociation with  subunits and termination of signaling via their effectors 
(Figure 1-3C).27 However, this intrinsic GTPase activity is quite slow and its function alone is 
insufficient to adequately explain how rapidly certain GPCR signaling pathways, such as those 
regulating photoreceptor activity in the retina, are terminated.28  Members of the regulator of G 
protein signaling (RGS) family solve this apparent problem. RGS proteins bind to active  subunits 
following GPCR stimulation and stabilize the GTP-to-GDP transition state to enhance hydrolysis 
and accelerate signal termination (Figure 1-3D).29 As such, they belong to the GTPase activating 
protein (GAP) family, which includes GAPs for small GTPases such as Ras and Rho.30 This GAP 
function is dependent upon the highly conserved RGS domain: an ~120 amino acid bundle of  
helices periodically interrupted by variable linker regions.29 
To date, at least 20 canonical RGS proteins (with described GAP activity towards 
Gq and/or Gi subunits) and many more RGS-like proteins (with GAP-deficient or more distantly 
related RGS homology domains) have been discovered.31 Canonical RGS proteins have been 
classified into four major subfamilies based on sequence homology within the RGS domain: A/RZ, 
B/R4, C/R7 and D/R12.32 A/RZ and B/R4 subfamilies are the most closely related and have 
relatively simple RGS domain-flanking regions. Their only putative domains consist of an N-terminal 
poly-cysteine region, which can be reversibly palmitoylated, and/or an amphipathic helix, both of 
which are thought to promote membrane anchoring.33,34 C/R7 subfamily members possess G-like 
(GGL) domains, that interact with G5 subunits, as well as N-terminal Disheveled/EGL-
10/Pleckstrin homology (DEP) domains, archetypically involved in plasma membrane 
anchoring.35,36 D/R12 family members are more diverse in their domain structure. RGS12 and 
RGS14 share C-terminal tandem Rap-binding domain (RBD) motifs, that provide scaffolding for 
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mitogen-activated protein kinase (MAPK) proteins, and GoLoco motifs, that act as guanine 
nucleotide dissociation inhibitors (GDIs) towards Gi family  subunits.37,38 Additionally, RGS12 has 
an N-terminal PSD-95/Discs-large/ZO-1 homology (PDZ) domain, mediating interactions with 
certain GPCRs, and a phosphotyrosine-binding (PTB) domain, whose phosphorylation promotes 
association with a transmembrane calcium channel.39,40 RGS proteins have many diverse biological 








Figure 1-3. GPCR signaling and RGS proteins. (A) At rest, GDP-bound  and  
subunits are associated in a heterotrimeric complex and interact with their G protein-
coupled receptor. (B) Upon activation of the GPCR, classically via a bound agonist, GDP 
is exchanged for GTP, and the  and  subunits dissociate. This exposes binding sites 
for downstream effectors (yellow), which can initiate the resulting signaling cascades. (C) 
 subunits have intrinsic GTPase activity and hydrolyze GTP back to GDP to cause 
reassociation of the heterotrimeric complex which terminates signaling. However, this 
process is relatively slow (t1/2 ≈ s). (D) RGS proteins (purple) bind to the  subunit to 
enhance GTPase activity and accelerate signal termination (t1/2 ≈ ms). GDP, guanosine 5’-




1.4 RGS in Platelets 
 Rapid activation of platelets is a crucial step in the hemostatic response to injury to prevent 
unnecessary bleeding and GPCRs are the predominant means by which this is accomplished. 
While these signaling networks have been well-described, less is known about the mechanisms 
that regulate these networks to prevent unnecessary or excessive platelet activation. RGS proteins 
represent one such mode of regulation and two are commonly and predominantly expressed in 
both human and mouse platelets: RGS10 and RGS18.41-43 
 RGS18, a member of the B/R4 RGS subfamily, is limited in expression to hematopoietic 
cells, including platelet progenitor megakaryocytes and osteoclasts.44-46 RGS18 is slightly larger 
than RGS10 at ~28 kDa, but is still amongst the smallest and simplest of RGS proteins with a single 
putative amphipathic helix N-terminally flanking the RGS domain core (Figure 1-4).45 Studies 
suggest that RGS18 binds with a similar affinity to both Gi and Gq  subunits, but not Gz, G12, or 
Gs.46,47  
 RGS10, a member of the D/R12 subfamily, is widely expressed in a variety of tissues and 
cell types including ovaries, bones, T-cells, neurons, heart, and platelets.48-52 While its functions 
are diverse depending on the cell type, they are mostly consistent with its canonical role as a 
regulator of GPCR signaling. RGS10 is amongst the smallest and simplest of the RGS proteins at 
~20 kDa, and does not appear to possess any putative functional domains outside of its RGS 
domain (Figure 1-4).53 RGS10 has been shown to selectively interact with Gi family  subunits, with 
only very weak binding reported for Gq and none for Gs.47,54 And in cells other than platelets, various 
mechanisms, including transcriptional regulation, palmitoylation and phosphorylation, have been 
shown to modulate RGS10 activity (Figure 1-4).55-58 Furthermore, at least two reports suggest non-
canonical functions for RGS10 independent of GAP activity, although the precise mechanisms 
involved are unclear.57,59 





Figure 1-4. RGS10 and RGS18 protein sequence features. Graphical depiction of 
amino acid sequences for human RGS18 (Q9NS28-1) and RGS10 isoform 3 (O43665-3). 
Phosphorylation sites (red) and palmitoylation sites (yellow) were empirically determined. 
The putative amphipathic helix (green) has been predicted from the sequence and is not 
resolved in the available NMR structure. The RGS domain (cyan) is both necessary and 
sufficient to provide GTPase activity towards  subunits. Graphic was prepared using the 




1.4.1 RGS deletion 
 In order to more precisely understand the physiological impacts of RGS10 and RGS18 in 
the context of platelets, researchers have relied upon genetically modified mouse models deficient 
in expression of these proteins, or knockouts (KOs; RGS-/-). Comparing these KO mouse models 
to their genetically identical wild type counterparts has become one of the most widely used 
methods for investigating protein function in a context relevant to human biology and disease.60  
 Deletion of RGS18 results in a mild thrombocytopenia, which is reportedly due, in part, to 
a decrease in the number of mature megakaryocytes as well as their platelet producing potential. 
Furthermore, the same study suggests that RGS18-/- renders platelets sufficiently hyperactive in 
circulation to result in spontaneous aggregation, which appears to be mediated by its canonical 
function regulating GPCR signaling, primarily Gq. It is suggested that this may be another 
mechanism that leads to the mild thrombocytopenia observed.61 Later reports confirm the GPCR-
mediated hyperactive phenotype of RGS18-/- platelets in vitro and in vivo, using aggregometry, tail 
clip hemostasis assays, and a ferric chloride thrombosis model.62 
 Results from our work and that of others suggest that deletion of RGS10-/- has no effect on 
platelet counts, but it does result in similarly hyperactive platelets. Using aggregometry and flow 
cytometry, Hensch et al showed an increase in platelet activation in response to GPCR-stimulating 
agonists.63 However, the authors present evidence suggesting that effects of these agonists, which 
include Gq-stimulating thrombin, and Gq/13 stimulating TxA2 analogue (U46619), are due primarily 
to secondary signaling via ADP stimulation of P2Y12 receptors.63 Because P2Y12 couples to Gi2, this 
suggests that RGS10 preferentially interacts with these  subunits, which is consistent with 
previous reports in vitro.47,54 Lastly, the authors show a hyperactive platelet phenotype in vivo that 
is strikingly similar to RGS18-/- mice, using the same tail clip hemostasis assay, and ferric chloride 
thrombosis model. While our results are largely consistent (presented in detail in Chapter 2), we 
expand upon the phenotypic analysis to explore the architecture of hemostatic plugs in vivo and 
present data suggesting that both Gq and Gi2 are impacted by RGS10 deletion. Furthermore, we 
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show that RGS10 is phosphorylated and binds to both spinophilin and 14-3-3 in an agonist-
selective manner, which may regulate its function in vivo.64  
In summary, these KO studies suggest overlapping yet divergent roles for RGS10 and 
RGS18 in platelet biology, which may be a result of their specificities towards individual  subunits, 
interactions with regulatory adapters, post-translational modifications or intracellular localization. 
However, it is still unclear the extent to which both proteins cooperate with (or possibly counteract) 
one another to regulate platelet activation in the context of hemostasis. 
1.4.2 RGS-insensitive mutations in G subunits 
 While RGS KOs provide valuable information about the individual role of each protein, most 
cells express multiple RGS that may have partially redundant functions. To circumvent this 
problem, investigators have turned to  subunits harboring RGS-insensitive substitutions: point 
mutations that disrupt RGS binding without impacting downstream effector interactions required for 
signaling. This allows one to probe the effects of all RGS proteins on individual  subunit-mediated 
signaling networks.65 
 Shortly after the discovery of these types of mutations, mouse models were generated to 
determine their physiological impacts. One such model was a glycine to serine substitution at 
position 184 (G184S) of the Gi2  subunit.66 Investigators from our lab used this model to probe the 
platelet-dependent effects of RGS-insensitive Gi2, coupled to the primary ADP receptor in platelets, 
P2Y12. By aggregometry, intravital microscopy, and microfluidics assays, they showed that 
heterozygous mice (G184S/+) had platelets that were hyperactive in response to GPCR agonists 
but not ITAM agonists, such as collagen. Furthermore, they demonstrated increased Gi2-mediated 
signaling via cAMP and Akt phosphorylation assays, but no increase in Gq-mediated signaling 
assessed by calcium mobilization.67 
 A similar discovery made for Gq was first demonstrated in yeast and followed by Chinese 
hamster ovary cells exogenously expressing recombinant human proteins. Analogous to the 
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mutation described for Gi2, a glycine to serine substitution at position 188 (G188S) of human Gq 
rendered the protein insensitive to RGS-dependent GAP activity and subsequent signal 
attenuation. And similarly, in these simplified models, the mutation did not appear to have any 
impact on interactions with downstream effectors required for signal transduction.68 To explore the 
impact of RGS-mediated regulation of Gq in platelet activation and hemostasis, our lab used 
CRISPR-Cas9 and homology directed repair to create this substitution in mice (described in detail 
in Chapter 4). Unexpectedly, our phenotypic, biochemical and structural analyses of this model 
suggested that the G188S mutation does indeed disrupt other downstream effectors, like PLC, in 
addition to RGS proteins. The resulting platelets almost completely phenocopy a Gq-/-, further 
supporting this notion. Why this phenomenon is not observed in yeast or a mammalian cell-based 
model but is observed in mice remains incompletely understood. 
 Overall, these results suggest that RGS-insensitive mutations are a useful tool to probe 
the effects of RGS proteins on individual  subunits. However, caution and diligence must be 
observed when attempting to translate results observed in vitro to an in vivo model. 
1.4.3 Regulators of RGS function 
While improving our understanding of how RGS proteins impact GPCR signaling networks 
remains important, equally as important is understanding how RGS proteins themselves are 
regulated within platelets. 
 Phosphorylation of RGS10 and RGS18 in platelets in response to agonist stimulation was 
first reported by Garcia et al in 2004 following a differential platelet proteomic analysis. And while 
serine 49 (S49) was identified as a site for RGS18, they did not determine the site(s) of RGS10 
phosphorylation.69 A later study by Gegenbauer et al used immunoblotting, transfected variants, 
and immunoprecipitation to identify the adapter protein 14-3-3 as a phosphorylation-dependent 
regulator of RGS18. Their results identified two additional sites of phosphorylation on RGS18, 
serine 216 (S216) and serine 218 (S218) (Figure 1-4). Their proposed model, based on the data 
presented, suggests that RGS18 is basally phosphorylated on S218 at rest and weakly or 
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transiently associated with 14-3-3 Stimulation with a Gq-activating agonist results in 
phosphorylation at S49, which enhances interactions with 14-3-3, inhibiting RGS18 function to 
enhance Gq-mediated signaling. In contrast, inhibiting platelets with PGI2 or nitric oxide (NO) 
stimulates cyclic nucleotide-dependent kinases to phosphorylate S216, causing dissociation of 
RGS18 and 14-3-3, and enhancing its ability to attenuate Gq-signaling.70,71 These results are 
consistent with the role of RGS18 as a negative regulator of platelet activation and suggest that its 
activity is modified depending upon the biological context. Additional studies described 
phosphorylation of RGS10 at serine 168 (S168) via a PKA-dependent mechanism in nucleated 
cells (Figure 1-4). This results in nuclear translocation, thereby inhibiting its ability to act upon 
plasma membrane-associated  subunits, but had no apparent impact on GAP activity in vitro.56 
However, phosphorylation of RGS10 and its potential role in anucleate platelets has yet to be fully 
investigated. RGS10 can also be reversibly palmitoylated at cysteine 66 (C66), and this reportedly 
enhances GAP activity during receptor-stimulated, steady-state GTP hydrolysis.55 
 Studies from our lab have revealed another regulator of RGS function in platelets: 
spinophilin. First discovered in rat brain as a protein phosphatase 1 (PP1)-inhibiting scaffold 
protein,72 spinophilin was later shown to interact with a subset of RGS proteins and specifically 
regulate activity of RGS2.73 Investigators from our lab later demonstrated expression of spinophilin 
in both human and mouse platelets, its ability to bind both RGS10 and RGS18, and a 
phosphorylation-dependent, agonist-specific mechanism by which its interactions with RGS 
proteins in platelets are modulated (described in detail in Chapter 2).74 Furthermore, data from KOs 
and a binding-deficient variant suggest that spinophilin interacting with RGS in the context of 
platelets inhibits GAP function.74,75 This is in contrast to reports in nucleated cells suggesting that 
binding of RGS2 to spinophilin enhanced its function by localizing it to the -adrenergic receptor,73 




CHAPTER 2: Hemostatic Role and Regulation of RGS10 in Platelets 
2.1 Introduction 
 Human RGS10 was first discovered and characterized in 1996 as a GAP for Gi  
subunits,54 and its subsequent exogenous expression in cultured cell models was consistent with 
this analysis.55,56 In 2004, Garcia et al presented evidence that RGS10 (in addition to RGS18) was 
expressed in human platelets,69 but it was not until 2008 that the first RGS10-/- mouse model, 
generated using mouse embryonic stem cells and a randomized gene trapping method, was 
reported to explore its function in dopaminergic neurons.76,77 However, it was still unclear how this 
protein affected platelet signaling and responses within a physiological context.  
 Our lab was the first to present evidence that RGS proteins negatively regulate platelet 
signaling and activation, using the RGS-insensitive Gi2 G184S mouse model (described in 1.4.2). 
And since RGS10 is the most abundant RGS in both human and mouse platelets and purported to 
be selective for Gi  subunits, we relied upon the RGS10-/- mouse model to explore the specific 
function of RGS10 with respect to hemostatic platelet reactivity.  
 Overall, our findings show that, while similar in some respects, the Gi2 G184S model is 
not identical to the RGS10-/- model. This suggests that the RGS10 must be exerting its effects on 
other  subunits in addition to Gi2. In support of this notion, we show that both Gq and Gi2 signaling 
are impacted by RGS10 deletion, and that the nature of its impact depends upon specific receptors. 
Additionally, we provide evidence that RGS10 binds to both spinophilin and 14-3-3 at rest and 
dissociates in an agonist-selective manner, suggesting that both adapter proteins may provide 
potential modes of regulation. Lastly, we show that RGS10 is phosphorylated in platelets in an 





2.2 Materials and Methods 
2.2.1. RGS10-/- mouse model  
 RGS10-/- mice and wild type (WT) littermate controls were produced by crossing 
heterozygotes obtained from the Mutant Mouse Regional Resource Center (MMRRC, Chapel Hill, 
NC). The mice were obtained on a mixed 129/C57BL/6 background. Studies were performed using 
sex-matched littermates and carried out with Institutional Animal Care and Use Committee 
approved protocols. We genotyped the mice using a strategy developed by the MMRRC. The 
following primers were used in P R reaction. Forward primer: 5’-
CCTTCCTGAGCACTGGACAACTGAT-3’; Reverse primer 1: 5’-
ATAAACCCTCTTGCAGTTGCATC-3’; Reverse primer 2: 5’-AGGTGCTATGAAGCCTGGTTTGC-
3’.  We performed P R with the following conditions: denaturation at 95°C for 7 minutes; 35 cycles 
of (96°C for10 seconds, 60°C for 30 seconds, 68°C for 1.5 minutes); extension at 68°C for 7 
minutes. 
2.2.2. Hemostatic vascular injury model 
Hemostatic thrombus formation was observed in the cremaster muscle microcirculation of 
male mice aged 8-12 weeks essentially as previously described.78 Alexa Fluor 568–labeled anti-
 D41 F(ab’)2 fragments, Alexa Fluor 488–labeled anti–P-selectin, and Alexa Fluor 647-labeled 
anti-fibrin were administered via a catheter in the jugular vein. Arterioles 30-50 µm in diameter were 
studied. Penetrating vascular injuries were produced with a pulsed nitrogen dye laser fired through 
the microscope objective. Thrombus formation was observed for 3 min at 1.9 frames per second 
and analyzed using SlideBook 6 software (Intelligent Imaging Innovations, Denver, CO). For 
embolization studies, anti-CD41 labeled platelets accumulating at the injury site were acquired with 
4x4 binning and 4 millisecond exposure time; only the red channel was used in order to increase 
image acquisition to 35.5 frames/sec, with a total of 6300 frames collected in 3 minutes. Data were 
collected in a region of interest drawn downstream of the thrombus. 
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2.2.3 Clot retraction 
Visual assay: Whole mouse blood was drawn in 0.38% sodium citrate and centrifuged at 
200 × g to obtain platelet rich plasma. Samples were adjusted with platelet-poor plasma to 6×108 
platelets/mL, recalcified with 2 mM CaCl2 and stimulated with 10 U/ml thrombin. Clot retraction was 
recorded at 15-minute intervals at 37° C with a digital camera and analyzed using ImageJ software. 
 Automated light scattering assay: Blood was collected from the inferior vena cava of 
anesthetized mice into 3.8% sodium citrate. Clot size dynamics were tracked by measuring light 
scattering over time followed by computational processing of the serial images using a 
Thrombodynamics Analyzer System (HemaCore, Moscow, Russia). Plastic cuvettes (12 x 7 x 1 
mm) were prelubricated with a residual layer of 4% (v/v) Triton X-100 in phosphate-buffered saline 
to prevent fibrin sticking to the chamber. Samples were incubated with 2 mM CaCl2 at 37°C for 3 
minutes followed by addition of 5 U/mL thrombin to initiate clotting. Samples (80 µL) were quickly 
transferred to the cuvette, which was placed into the thermostatic chamber (37°C) between a red 
light-emitting diode and a CCD camera. Clot size was tracked from digitized images every 15 
seconds for 20 minutes and analyzed using ImageJ software.79 
2.2.4 Flow cytometry 
Platelet activation via flow cytometry was detected as previously described.80 Briefly, 
heparinized whole mouse blood was diluted 1:40 in modified Tyrode’s buffer (137 mM NaCl, 20 
mM HEPES, 5.6 mM glucose, 1 g/liter BSA, 1 mM MgCl2, 2.7 mM KCl, 3.3 mM, NaH2PO4, pH 7.4). 
and incubated with 1 mM aspirin and 1 U/ml apyrase for 30 mins at 37°C to eliminate secondary 
signaling via released TxA2 and ADP. The blood was incubated with agonists in presence of 
saturating amounts of fluorophore-conjugated mAbs directed towards activated IIb3 integrin 
(Jon/A-PE; Emfret Analytics, Wuerzburg, Germany) and P-selectin (FITC-labeled; BD Biosciences, 
San Jose, CA) for 15 min at room temperature and analyzed on a FACSCanto II (BD Biosciences, 
San Jose, CA). The platelet population was gated based on FSC/SSC and CD41 positivity (Alexa 
19 
 
Fluor 647–labeled F(ab’)2; BD Biosciences, San Jose, CA). For activation studies with ADP, 
platelets were incubated with 1 mM aspirin alone. 
2.2.5 Intracellular calcium mobilization 
Intracellular calcium was measured as previously described.81 Briefly, isolated platelets 
were suspended in Tyrode’s buffer without  a++ and loaded with fura-2/AM (5 μM) in the presence 
of Pluronic F-127 (0.2 μg/mL) for 20 minutes at 37° . The platelets were then washed and 
resuspended in Tyrode’s buffer with no extracellular  a++.  Changes in fura-2 fluorescence were 
detected with an SLM/Aminco AB2 spectrophotometer, exciting at 340 and 380 nm, and measuring 
emission at 510 nm. 
2.2.6 Akt phosphorylation 
Blood was collected from the inferior vena cava of anesthetized mice into 200 U/mL heparin 
diluted 9:1 by volume and centrifuged at 280 x g for 5 min. Platelet rich plasma (PRP) was carefully 
removed from the supernatant and supplemented with 1 μM PGE1 (Sigma-Aldrich, St. Louis, MO). 
PRP was loaded onto a 2 mL column of Sepharose 2B and eluted with Tyrode’s buffer containing 
1 mg/ml bovine serum albumin. The most turbid fractions collected were counted and adjusted with 
Tyrode’s buffer to 2 x 108 platelets/mL. Platelets were incubated with vehicle, agonists or 
antagonists at the concentrations outlined in the figures. Lysates were boiled in sample buffer prior 
to SDS-PAGE analysis. Immunoblots were performed with an anti-pAkt (Ser473) antibody before 
re-probing with anti-Akt antibody (Cell Signaling Technology, Danvers, MA). 
2.2.7 Washed human platelets 
 Blood was obtained from healthy donors using protocols approved by the University of 
Pennsylvania IRB. Written informed consent of all donors was obtained prior to blood collection. 
Blood was anticoagulated 1:5 with ACD (65 mM Na3 citrate, 70 mM citric acid, 100 mM dextrose, 
pH 4.4) and centrifuged at 129 x g for 20 min to obtain platelet rich plasma (PRP). PRP was then 
diluted 1:4 with HEN buffer (150 mM NaCl, 1 mM Na2EDTA, 10 mM HEPES, pH 6.5) containing 1 
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µM PGI2 prior to sedimentation at 341 x g for 10 min.  Washed platelets were then resuspended in 
Tyrode’s buffer to the desired concentration.  
2.2.8 Phosphorylation of RGS10 
Washed human platelets (prepared as outlined in 2.2.7) were adjusted to 1 x 109 /mL and 
supplemented with 1 mM CaCl2. Following preincubation with inhibitors, platelet suspensions were 
treated with agonists, as indicated, and then lysed with HaloTag buffer [150 mM KCl, 50 mM 
HEPES, 0.1% (w/v) CHAPS, 4% NP40, pH 7.4, 1X cOmplete EDTA-free protease inhibitor cocktail, 
1X PhosSTOP phosphatase inhibitor cocktail (Roche Diagnostics, Mannheim, Germany)]. Samples 
were then boiled in 1X Laemmli Sample Buffer (Biorad, Hercules, CA) and separated using a 12.5% 
SuperSep Phos-tag gel (198-17981; Wako Pure Chemical Industries, Osaka, Japan) according to 
manufacturer instructions. Following transfer to polyvinylidene difluoride membrane, 
immunoblotting was performed using goat -RGS10 (sc-6206; Santa Cruz Biotechnology, Santa 
Cruz, CA). 
2.2.9 Pull-down of platelet RGS10 
Halo-tagged human Gi2 (Halo-GNAI2) was overexpressed in CHO cells transfected with 
pFC27A-Gi2 vector (Promega, Madison, WI). Following sonication to lyse cells and centrifugation 
at 10,000 x g to pellet membranes, protein from supernatant was conjugated to Magne HaloTag 
beads (Promega, Madison, WI) according to manufacturer recommendations. Resting or 10 U/mL 
thrombin-stimulated washed human platelets (prepared as in 2.2.7) were immediately centrifuged 
at 775 x g for 3 minutes at RT, resuspended in HaloTag Buffer (as prepared in 2.2.9), and lysed by 
sonication. Following centrifugation at 10,000 x g to pellet membranes, supernatant containing 
soluble protein was supplemented with either GDP buffer (10 mM HEPES, 150 mM Na l, 50 μM 
EDTA, 0.0005% Triton X-100, 100 μM GDP, pH 7.5) or AMF buffer (GDP buffer, 10 mM MgCl2, 10 
mM NaF, 30 μM Al l3, pH 7.5). Washed Halo-GNAI2-Magne beads were added to samples and 
incubated for 2 hours while rotating at 4°C. Following three additional washes, Gi2 and bound 
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proteins were eluted from the magnetic beads with 1 μL of ProTEV tobacco etch virus protease 
(Promega, Madison, WI) for 90 minutes while rotating at room temperature. His-tagged ProTEV 
was removed from the solution by further incubation with HisLink resin (Promega, Madison, WI) for 
an additional 20 minutes. After allowing HisLink beads to settle in a magnetic rack, Input, Wash 
(first after coincubation), and Eluate samples were carefully removed and analyzed by SDS-PAGE 
with Phos-tag gels and immunoblotting (as outlined in 2.2.9). 
2.3 Results 
2.3.1 RGS10 deletion modifies the structure of hemostatic plugs 
To assess hemostatic platelet function in vivo, mice were injected with fluorescent 
antibodies and imaged using confocal intravital microscopy following a penetrating laser injury. Our 
lab has previously demonstrated this to be a model of hemostasis rather than thrombosis because 
the endothelium is completely penetrated, blood leaks out initially, and the hole is rapidly sealed in 
a platelet-dependent manner.78 The platelet plug that follows consists of a highly activated, densely 
packed, P-selectin(+) core overlaid by a less activated, more loosely packed, P-selectin(-) shell. 
And while growth of the shell relies primarily upon the release of secondary signaling agonists such 
as TxA2 and ADP,82 the initial core of platelets (as well as fibrin deposition) depends upon thrombin, 
which remains localized to the site of the injury.83 
When comparing RGS10-/- mice to their respective WT controls, the initial rate of 
accumulation as well as peak total platelet accumulation does not differ appreciably (Figure 2-1A, 
B). Furthermore, we observed no significant difference between the two genotypes with respect to 
growth of the P-selectin(+) core (Figure 2-1A,C) or fibrin deposition (Figure 2-1D). However, while 
the WT platelet area tends to decrease after reaching peak growth, RGS10-/- platelet area remains 
stable until the endpoint, which we can attribute to the P-selectin(─) shell (Figure 2-1A). 
At least two known phenomena contribute to the decrease in plug size following peak 
platelet accumulation in a normal mouse: embolization and retraction. Embolization, under these 
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conditions, occurs when less-activated platelets in the shell detach and are carried away, which 
suggests that a greater activation state is required for firm adhesion at the site of injury.78 To test 
for differences in embolization, the passage of platelet aggregates downstream of  a growing 
hemostatic plug were measured. While the number of emboli did not differ significantly during the 
initial growth phase of the plug up to peak accumulation, fewer emboli were observed for the 
RGS10-/- hemostatic plugs after peak accumulation (Figure 2-1E).  
Retraction of hemostatic plugs depends, in large part, on outside-in signaling via IIb3 
integrin.84,85 Interestingly, using two distinct assays, we observed a small but significant delay in 
retraction for the RGS10-/- blood when compared to WT controls following thrombin stimulation 
(Figure 2-1F,G). However, there was no difference in the degree of clot retraction at the endpoint 
in either assay. It is important to note, though, that the time scales for these various assays differ 
considerably. While cremaster laser injuries are captured over the course of 3 minutes, the visual 
and light scattering clot retraction assays occur over the course of 1 hour and 20 minutes, 
respectively. Thus, it is possible that RGS10-/- hemostatic plugs could consolidate to a similar 
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Figure 2-1. RGS10 deletion enhances the initial hemostatic response but 
delays clot retraction. Confocal intravital fluorescence microscopy was used to 
measure (A, B) platelet accumulation, (A, C) P-selectin expression, and (D) fibrin 
deposition. N = 78 injuries in 11 mice. (E) Embolization of platelets was measured by 
placing a virtual analysis window downstream of the site of injury and pooled into early and 
late time points for analysis. N = 19 injuries for WT and 18 injuries for RGS10-/- in 3 mice. 
Clot retraction was measured in (F) platelet rich plasma treated with 10 U/mL thrombin via 
a visual assay and (G) in whole blood samples incubated with 5 U/mL thrombin via a light 




2.3.2 RGS10 differentially affects specific GPCR signaling pathways 
To assess the activation-dependent hemostatic function of platelets in vitro, we used flow 
cytometry to measure -granule exocytosis and activated IIb3 integrin with anti-P-selectin-FITC 
antibodies and Jon/A-PE, respectively. Platelets in these studies were pretreated with apyrase and 
aspirin to limit secondary signaling effects via ADP and TxA2, respectively (except when using ADP 
as the agonist, pretreatment was with aspirin only). For PAR4 activating peptide (AYPGKF)-
mediated P-selectin exposure, RGS10-/- platelets exhibited a left-shift in the dose-response but 
were no different at minimally or maximally activating concentrations (Figure 2-2A). In contrast, 
RGS10-/- platelets had a 6.7-fold increase in maximum P-selectin exposure in response to U46619, 
a TxA2 mimetic (Figure 2-2C) and a similar pattern for ADP, with a 10.3-fold increase in maximum 
P-selectin exposure (Figure 2-2E). Additionally, nearly identical IIb3 integrin activation response 
patterns were observed for all agonists, with a left-shift in dose-response for AYPGKF (Figure 2-
2B), a 4.1-fold increase in maximal signal for U46619 (Figure 2-2D), and a 5.5-fold increase in 
maximal signal for ADP (Figure 2-2F). These results support the notion that both -granule 
exocytosis and IIb3 integrin activation as a measure of GPCR-dependent platelet activation are 






















   
 
   
    
Figure 2-2. RGS10 deletion increases integrin activation and -granule 
exocytosis. Platelets were stained with fluorophore-conjugated antibodies against (A, C, 
E) P-selectin or (B, D, F) IIb3 integrin (Jon/A) after incubation with (A, B) PAR4 agonist 
peptide (AYPGKF), (C, D) a TxA2 mimetic (U46619), or (E, F) ADP at the concentrations 




2.3.3 RGS10 regulates Gq- and Gi-mediated signaling in platelets 
As mentioned in 1.2, Gq-mediated responses result in, amongst other things, production of 
IP3 that stimulates Ca2+ release from the platelet dense tubular system. As a potent secondary 
signaling molecule, Ca2+ is involved in various activation events, including cytoskeletal 
rearrangements mediated, in part, by myosin light chain phosphorylation.86 To probe the magnitude 
and kinetics of Ca2+ mobilization, platelets were preloaded with the ratiometric  Ca2+ sensor, fura-
2, prior to agonist stimulation. For lower doses of PAR4 activating peptide (100 μM), the initial rate 
and the maximum amplitude of Ca2+ release is increased significantly in RGS10-/- platelets (Figure 
2-3A, B). However, those differences are no longer observed at higher concentrations of agonist 
(500 μM). Interestingly, in response to both U4  19 and ADP, there appears to be a significant 
increase in the maximum amplitude of Ca2+ release but no difference in initial rates (Figure 2-3A, 
B). These results would appear to be largely consistent with what we had observed using flow 
cytometry. Furthermore, RGS10-/- platelets exhibit a significant increase in myosin light chain 
phosphorylation following stimulation with PAR4 activating peptide, a secondary readout for Gq-
mediated signaling (Figure 2-3C). 
G subunits, derived from Gi subunit dissociation, activate PI3K which is involved in 
the phosphorylation and subsequent activation of the serine/threonine kinase, Akt.87-89 Thus, to 
specifically probe effects of RGS10 deletion on Gi-mediated signaling, we measured Akt serine 473 
phosphorylation (pAkt) in stimulated platelets via phosphospecific antibodies and immunoblotting. 
In response to ADP, pAkt was significantly increased in RGS10-/- platelets. This pattern was 
unaffected by the P2Y1 inhibitor, MRS2500, but  the response was ablated by the P2Y12 inhibitor, 
cangrelor, consistent with the notion that Akt phosphorylation is mediated by P2Y12 but not P2Y1 
(Figure 2-3D).88 Furthermore, we observed no differences between RGS10-/- and WT platelets in 
response to high dose PAR4 activating peptide (350 μM), which directly stimulates Gq-mediated 
signaling. However, like with ADP, we did see decreases in pAkt responses of both genotypes in 
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the presence of cangrelor but not MRS2500, suggesting that the PAR4 response is mediated, at  
least in part, by secondary signaling via released ADP acting upon P2Y12 (Figure 2-3D).  
 Figure 2-3. RGS10 regulates Gq- and Gi2-mediated signaling in platelets. (A) 
Fura-2-loaded platelets were stimulated with agonists as indicated to measure Ca2+ 
mobilization. (B) Quantification of Ca2+ experiments. N = 4. (C) Washed platelets incubated 
for 3 minutes with 350 μM AYPGKF were lysed and analyzed by immunoblotting for myosin 
light chain Thr18 and Ser19 phosphorylation. N = 4 (D) Gel-filtered platelets were 
stimulated with agonist ± inhibitors as indicated, lysed and analyzed by immunoblotting for 
Akt Ser473 phosphorylation. N = 5. All results represented as mean ± SEM; * = P < 0.05. 
 



















2.3.4 Interactions between RGS10 and putative regulators in platelets 
  Previous work from our lab has shown that both RGS10 and RGS18 are capable of 
binding to spinophilin (SPL) at rest but dissociate following Gq- or Gs-mediated stimulation (see 
1.4.3). Additional studies with SPL-/- mice and RGS binding-deficient variants have led to 
hypothesis that binding to SPL inhibits RGS function in platelets and that RGS release constitutes 
a mode of negative feedback regulation, although this has yet to be tested directly.74,75   
Additionally, others have shown that binding of RGS18 to 14-3-3 is enhanced by Gq-mediated 
signaling, but inhibited by Gs-mediated signaling, suggesting another mode of negative feedback 
regulation.70,71 Therefore, we sought to explore how these adapter proteins might be interacting 
with RGS10 using immunoprecipitation. It is important to note, however, that due to limitations with 
available antibodies, these analyses were carried out with human platelets rather than mouse 
platelets. 
In response to more potent Gq-stimulating agonists, such as PAR1 activating peptide 
(SFLRRN) or U46619, RGS10 appears to dissociate from SPL within 3 minutes (Figure 2-4A). 
However, in response to weaker Gq- and Gi-specific agonist, ADP, dissociation is primarily 
dependent upon secondary signaling, likely through TxA2, as the amount of dissociation is 
considerably diminished in the presence of aspirin (Figure 2-4B). As for the non-GPCR agonist, 
collagen, dissociation is entirely dependent upon secondary signaling, as aspirin and apyrase 
pretreatment blocks any appreciable dissociation (Figure 2-4A). Furthermore, forskolin, which 
directly activates adenylyl cyclase (AC), or PGI2 which activates Gs-coupled receptors upstream of 
AC, also results in dissociation of this complex, which is more robust in the presence of the 
phosphatase inhibitor, okadaic acid (Figure 2-4C). These results are consistent with what has 
previously been demonstrated for RGS18, suggesting that agonist-dependent phosphorylation of 
SPL impacts RGS interactions. Additionally, within 1 minute of thrombin stimulation, RGS10 
completely dissociates from 14-3-3 (Figure 2-4D), which is in direct contrast to what had previously 

















Figure 2-4. RGS10 interacts with spinophilin and 14-3-3. (A) Human platelets 
were incubated for 3 minutes with 50 μM PAR1 agonist peptide (SFLLRN), 10 μM TxA2 
mimetic (U4  19), 10 μM ADP, or 10 μg/mL collagen in the presence of absence of 100 
μM aspirin (ASA) and 1 U/mL apyrase (APY), as indicated. Lysates were precipitated with 
anti-RGS10 and probed for spinophilin (SPL) before reprobing for RGS10. N = 3. (B) 
Human platelets were incubated for 3 minutes with 10 μM ADP in the presence or absence 
of 100 μM aspirin (ASA), as indicated. Proteins were precipitated and immunoblotted as in 
A. N = 4. ( ) Human platelets were incubated with 20 μM forskolin (Forsk) or 15 μM PGI2 
in the presence or absence of okadaic acid, a phosphatase inhibitor, as indicated. Proteins 
were precipitated and immunoblotted as in A. N = 4. (D) Human platelets were incubated 
with 1 U/mL thrombin for the times indicated and then lysed. 14-3-3 was precipitated with 
anti-RGS10 prior to immunoblotting. N = 2. All quantifications, except those shown in D, 




2.3.5 Platelet activation-dependent RGS10 phosphorylation may impact G interactions 
 Prior work in cultured nucleated cells has shown that RGS10 is phosphorylated on S168 
in a PKA-dependent manner. This results in translocation of RGS10 to the nucleus, where it can 
no longer interact with G subunits in the plasma membrane but has no apparent direct impact on 
GTPase activity.56 Additional work with phospho-resistant variants of RGS10 (S168A) suggests 
that PKA-dependent phosphorylation may be important in mediating its role in protection against 
neurotoxicity, although the precise mechanisms of this role have not yet been clearly defined.90 
Thus, we sought to explore whether or not RGS10 undergoes phosphorylation in platelets and what 
signaling pathways may be involved.  
Human platelets were stimulated with several agonists, lysed and separated on Phos-tag 
gels, which provide improved resolution of phosphorylated species that bind specifically to the 
embedded Phos-tag molecule. Unexpectedly, PGE1 incubation, which stimulates Gs and 
subsequent PKA activation in platelets, did not result in any band shifts indicative of a 
phosphorylation event, as was hypothesized based on observations in the literature (Figure 2-5A). 
However, PAR1 activating peptide (SFLLRN) results in at least one (and possibly two) distinct band 
shift(s) to a higher apparent molecular weight (p2 and p1) indicative of a phosphorylated species. 
The same is true for ADP, although to a lesser extent (Figure 2-5A). Incubation with phosphatase 
led to a partial reduction in the intensity of p2 bands and an increase in the basal (b) bands, 
suggesting that these shifts are indeed due to phosphorylation. Additionally, we observed a dose-
dependent increase in phosphorylation of RGS10 in response to thrombin (PAR1 and PAR4 
activator), although the p1 band only becomes visible after partial dephosphorylation with calf 
intestinal phosphatase (Figure 2-5B). We also demonstrate that stimulation with high doses of 
either SFLLRN, AYPGKF or both results in RGS10 phosphorylation, indicating contributions from 
both PAR1 and PAR4 receptors (Figure 2-5C). Since these receptors couple to Gq, which results 
in calcium flux, we stimulated with the calcium ionophore, A23187, to see if phosphorylation was 
calcium dependent.  A23187 can directly induce RGS10 phosphorylation, which is almost 
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completely reversed by treatment with phosphatase, indicating the involvement of calcium in 
RGS10 phosphorylation (Figure 2-5C). Incomplete loss of these p1 or p2 bands after phosphatase 
incubation indicates incomplete dephosphorylation, which is likely due to non-ideal conditions for 
phosphatase activity. It is also worth noting that Phos-tag gels are extremely sensitive to minor 
differences in buffer composition, which is why we often observe warping of the protein molecular 
weight ladder lanes and inconsistent resolution of bands from experiment to experiment.   
A similar result was observed for PAR4 activating peptide (AYPGKF) stimulation of mouse 
platelets, with only a single distinct low molecular weight band at rest (b) and two distinct higher 
molecular weight species appearing after stimulation (p1 and p2) (Figure 2-5D). Since the 
magnitude of band shifts in Phos-tag gels is proportional to the degree of phosphorylation, we 
hypothesize that these bands indicate a singly (p1) and doubly (p2) phosphorylated species. 
Further, the pattern is similar but significantly weaker in intensity for RGS10+/- mouse platelets, 
providing further evidence that this signal is specific to RGS10. These results, combined with those 
observed above, indicate that activation-dependent RGS10 phosphorylation is common to both 
human and mouse platelets. 
To further elucidate the signaling mechanisms involved in RGS10 phosphorylation, we 
preincubated human platelets with inhibitors and stimulated with a variety of agonists (Figure 2-
5E). Thrombin stimulation results in a band shift that is consistent with previous observations, and 
this is not inhibited by preincubation with aspirin (to block secondary signaling via TxA2), apyrase 
(to block secondary signaling via ADP), KT 5720 (a PKA inhibitor), Saracatinib (a Src Family Kinase 
inhibitor), or CAY10505 (a PI3K inhibitor).91-93 This indicates that secondary signaling is not 
required for RGS10 phosphorylation via thrombin and that these various kinases are not involved. 
U46619 (a TxA2 mimetic) results a similar pattern although the p1 band appears to predominate 
over the p2 band and is unaffected by treatment with aspirin and apyrase. ADP stimulation only 
results in a very weak band shift and only of the p1 species, which is almost completely blocked by 
treatment with aspirin (Figure 2-5E). This suggests that ADP-mediated phosphorylation of RGS10 
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is primarily mediated by secondary signaling via TxA2, and thus not likely dependent on primary 
P2Y1 or P2Y12 signaling. Interestingly, GPVI stimulation via convulxin also results in the 
appearance of both p1 and p2 species which is unaffected by secondary signaling inhibitors (Figure 
2-5E). This suggests that RGS10 phosphorylation may be mediated by signaling mechanisms that 
are common to GPVI and GPCR signaling pathways. 
Since our previous evidence suggested that calcium ionophore could induce RGS10 
phosphorylation, we hypothesized that calcium mobilization would be upstream of the responsible 
kinase(s). This is consistent with our results for both Gq-coupled GPCR agonists as well as GPVI 
agonists, because these two signaling pathways converge at PLC activation, which generates IP3 
to stimulate calcium flux and DAG to stimulate PKC activation. To further test this, platelets were 
preloaded with BAPTA-AM, an intracellular calcium chelator, and then stimulated with thrombin in 
the presence or absence of extracellular calcium. BAPTA-AM dose dependently inhibited RGS10 
phosphorylation (at least of the p2 species), which was further reduced if no extracellular calcium 
was present (Figure 2-5F), indicating that calcium plays at least a partial role in mediating RGS10 
phosphorylation. Because PKC isoforms are activated downstream of these signaling pathways, 
we next asked whether inhibition would reduce RGS10 phosphorylation. Treatment with a pan-
PKC inhibitor, GF109203X, resulted in a similar dose dependent decrease in phosphorylation of 
RGS10.94 And at the highest concentrations tolerated by platelets, RGS10 phosphorylation was 
almost completely ablated (Figure 2-5F), suggesting that PKC isoforms are likely responsible for 
RGS10 phosphorylation. This was further confirmed by direct stimulation with phorbol 12-myristate 
13-acetate (PMA), which directly activates PKC.95 The response to PMA was virtually identical to 
that of thrombin and was inhibited to a similar extent by GF109203X (Figure 2-5G). Lastly, we lysed 
resting or thrombin-stimulated human platelets and attempted to pull-down RGS10 with Halo-
Gi2 in the presence of GDP alone (to mimic the inactive state) or GDP + AlF4- (to mimic the 
transition state). RGS10 was partially phosphorylated in the resting condition, but the predominant 
species was unphosphorylated. Interestingly, Gi2 was unable to pull down the largely 
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dephosphorylated species of RGS10. However, after thrombin stimulation, almost all the RGS10 
was phosphorylated, and a at least a portion appeared to bind to Gi2 (Figure 2-5H) This suggests 




Figure 2-5. Platelet RGS10 undergoes activation-dependent phosphorylation (on 
following page). (A) Washed human platelets were incubated with 50 μM SFLLRN, 20 μM ADP, 
or 10 μM PGE1, lysed, and incubated in the presence or absence of 400 U of lambda phosphatase 
as indicated prior to Phos-tag immunoblotting. (B) Washed human platelets were incubated with 
increasing concentrations of thrombin as indicated, lysed and then incubated in the presence or 
absence of 20 U calf intestinal phosphatase (CIP) prior to Phos-tag immunoblotting.(C) Washed 
human platelets were treated with SFLLRN (PAR1 agonist peptide), AYPGKF (PAR4 agonist 
peptide), a combination of the two, or A23187 (calcium ionophore), lysed, and incubated in the 
presence or absence of 20 U CIP prior to Phos-tag immunoblotting. (D) Washed platelets from wild 
type or RGS10+/- mice were incubated with 350 μM AYPGKF, lysed and analyzed by Phos-tag 
immunoblotting. (E) Washed human platelets were stimulated with 10 U/mL thrombin, 50 μM TxA2 
mimetic (U4  19), 20 μM ADP, or 1 μg/mL convulxin ( VX) in the presence or absence of 1 mM 
aspirin (ASA), 1 U/mL apyrase (APY), 0.1 μM PKA inhibitor (KT 5720; PKAi), 0.1 μM Src Family 
Kinase inhibitor (Saracatinib; SFKi), 20 μM PI3K inhibitor ( AY10505; PI3Ki), and 5 mM EGTA. 
Lysed samples were then analyzed by Phos-tag immunoblotting. (F) Washed human platelets were 
treated with 1 U/mL thrombin in the presence or absence of increasing concentrations of 
intracellular calcium chelator (BAPTA-AM) or PKC inhibitor (GF109203X), and/or 1 mM CaCl2 
(Ca2+), lysed and analyzed by Phos-tag immunoblotting. (G) Washed human platelets were treated 
with 1 U/mL thrombin or 1 μM phorbol 12-myristate 13-acetate (PMA) in the presence or absence 
of PKC inhibitor (GF109203X), lysed and analyzed by Phos-tag immunoblotting. (H) Washed 
human platelets were incubated in the presence or absence of 1 U/mL thrombin, lysed and subject 
to pull-down via magnetic bead-bound Halo-Gi2 in the presence of GDP or GDP + AlF4-. Total 
lysate (Input), washes after the final incubation with Halo-Gi2 (Wash) and eluate (E1) after tobacco 
etch virus cleavage of Gi2 from the magnetic beads were analyzed by Phos-tag immunoblotting. 
Arrows indicate: b, basally phosphorylated or unphosphorylated species; p1, first phosphorylated 









 Using the cremaster laser injury model to study hemostasis in vivo, we’ve gained valuable 
insights into the biochemical and biophysical determinants of hemostatic plug formation that are 
modulated by RGS10 deletion. And in combination with our in vitro studies, we have expanded our 
working model for hemostasis that highlights the importance of RGS10 and its regulation. 
Deletion of RGS10 results in stabilization, but no difference in peak accumulation, of the 
P-selectin(─) shell in vivo, which is driven primarily by released ADP and TxA2. A similar pattern was 
also previously observed for Gi2G184S/+ mice, hemizygous for a substitution that makes Gi2 
insensitive to RGS regulation, with an expansion of the shell.78 However, in this model, the peak 
accumulation of P-selectin(─) platelets was significantly greater, in addition to being more stable 
over time. This would indicate that the net effect of RGS-insensitive Gi2G184S/+ is greater than that 
of RGS10 deletion alone and suggests contributions to Gi2-mediated signaling from additional RGS 
in platelets, such as RGS18. Furthermore, while the effects of RGS-insensitive Gi2G184S/+ are 
limited to Gi2-mediated signaling, RGS10 deletion appears to impact both Gq and Gi signaling 
pathways, as demonstrated by our Ca2+ and Akt phosphorylation assays, respectively. This would 
indicate that RGS10 regulates both Gq and Gi2 in platelets, although the extent to which it does 
so is not entirely clear. This is consistent with concurrent studies by Hensch et al, which showed 
that pretreatment of RGS10-deficient platelets with apyrase led to transient aggregation following 
stimulation with low-dose PAR4 agonist peptide (40 μM) that was not observed in the absence of 
apyrase.63 Since apyrase indiscriminately hydrolyzes ADP, which stimulates both Gq-coupled P2Y1 
receptors and Gi2-coupled P2Y12 receptors, it is likely that RGS10 limits signaling downstream of 
both of these secondary signaling pathways to prevent aggregation in response to submaximal 
PAR stimulation. 
In contrast to our U46619 and ADP flow cytometry results, we see only a slight but 
significant left-shift in the dose response curve for PAR4 agonist peptide stimulation with no 
increase in the maximal signal. However, we also do not see any differences in the P-selectin(+) 
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core, driven by local concentrations of thrombin, which cleaves and activates PARs. One possible 
explanation for this apparent discrepancy is that platelets in the core of a hemostatic plug, where 
thrombin concentrations are high and limited in diffusion by high packing density,85 are uniformly 
reaching maximal activation and fully degranulating. Since the differences that we observed for 
PAR activation in vitro disappear at maximal dose, the inability for thrombin to diffuse outward to 
less activated platelets could explain why the core size does not differ significantly. Another 
possibility is that RGS10, in isolation, does not significantly contribute to limiting platelet activation 
(and more specifically degranulation) once a certain threshold of activation has been reached. 
While we may not actually be able to reach this threshold in vitro with individual agonists, the 
complex microenvironment of a growing hemostatic core in vivo contains a milieu of additional 
stimuli that may overwhelm or downregulate RGS10-mediated regulation.  
Additionally, we have shown that RGS10, much like RGS18, can bind to spinophilin and 
14-3-3 in an agonist dependent manner. Interestingly, stimulation with activators like PAR1 
activating peptide or U46619 (Gq- and G13-coupled agonists) but not ADP (Gq- and Gi2-coupled 
agonist) or collagen (non-GPCR agonist) results in dissociation of the RGS10:SPL complex. 
Furthermore, platelet inhibitors, like PGI2 (Gs-coupled agonist) also cause dissociation of the 
complex. Why, then, might signaling pathways that are classically thought to have opposing 
outcomes, generate similar results? And why do only a subset of platelet activating agonists cause 
dissociation of the RGS10:SPL complex? While there is little available evidence to support concrete 
conclusions, we propose a model in which RGS10 serves dual purposes: negative feedback 
regulation and constitutive attenuation.  
When the platelet is in circulation, multiple mechanisms, including PGI2 released from the 
endothelium, maintain platelets in a quiescent state. It would thus stand to reason that, under these 
conditions, RGS10 dissociates from spinophilin to act as a constitutive break to limit aberrant Gq or 
Gi2 signaling in vivo. Conversely, when platelet activation is required to stem bleeding, the process 
needs to occur rapidly. Thus, having RGS10 bound to SPL to inhibit its function in the earliest 
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stages of platelet activation may be beneficial for the most rapid and robust response. However, 
an excessive response would prove to be just as deleterious as an insufficient one, so RGS10 is 
released from SPL after signaling is initiated to limit excessive platelet deposition and clot growth 
via Gq and Gi2 signaling. What remains unclear, however, are the in vivo conditions under which 
RGS10 becomes bound to SPL initially. It is possible that there is a rapid transition during initial 
platelet deposition where ADP-mediated Gi2-coupled P2Y12 activation counteracts PGI2-mediated 
inhibition prior to thrombin and TxA2 generation. Under these conditions, RGS10 would thus bind 
to spinophilin, allow rapid platelet activation via Gq- and Gi2-dependent signaling, and then 
dissociate from spinophilin to attenuate signaling before it leads to uncontrolled clot growth. 
Lastly, we present evidence that RGS10 is phosphorylated in platelets in an agonist-
specific manner that may impact its interactions with G subunits. Notably, TP and PAR stimulation, 
which result in dramatic dissociation from SPL, also result in robust RGS10 phosphorylation. It is 
thus possible that phosphorylation of RGS10 plays a role in mediating its interactions with SPL 
(and 14-3-3). However, Gs stimulation does not appear to impact RGS10 phosphorylation while it 
does result in SPL dissociation. This could indicate that Gs-mediated RGS10:SPL dissociation 
occurs via mechanisms that are distinct from Gq-mediated RGS10:SPL dissociation, as was 
reported for RGS18.75 Why Gs/PKA is involved in RGS10 phosphorylation in nucleated cells but 
not platelets remains unclear. It is possible that these cells possess an intermediate kinase that 
platelets lack. Further, it is yet unclear what functional impact phosphorylation has on RGS10 in 
platelets. While it appears that it may impact interactions with G subunits, it remains to be seen 
whether this is effect is direct or indirect via interactions with an intermediate, such as SPL or 14-
3-3.      Additionally, we observe at least two distinct phosphorylated species in response to platelet 
activation, particularly under circumstances where we achieve optimal resolution. For more robust 
stimuli like thrombin (or PAR1/4 agonist peptides), the p2 species appears to predominate. Since 
the degree of shift in a Phos-tag gel is proportional to the degree of phosphorylation, it is 
conceivable that this species is multiply phosphorylated. With less robust stimuli, such as U46619 
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and ADP, the p1 species appears to predominate. This suggests that weaker stimuli do not result 
in the same degree of phosphorylation. Further, this correlation suggests that the p1 species may 
be a required intermediate to sequentially generate the p2 species. While we have yet to identify 
the exact kinases involved, our data suggest that this process is Ca2+ and PKC-dependent, 
consistent with the ability of both Gq GPCR and GPVI ITAM signaling to generate similarly 
phosphorylated species. Interestingly, we see that BAPTA-AM, an intracellular calcium chelator, in 
the absence of intracellular calcium is still unable to reduce phosphorylation to the same degree as 
GF109203X, a pan-PKC inhibitor. While it is certainly possible that our highest concentration of 
BAPTA-AM is insufficient to completely chelate all calcium, it may also suggest that at least some 
degree of phosphorylation is calcium independent. Indeed, in the presence of BAPTA-AM the p2 
species appears to completely disappear while the p1 species remains robust. Based on these 
results and those for PKC inhibition, we hypothesize that the p1 species is dependent upon novel 
PKC isoforms (which require DAG but do not require Ca2+ for activation) while the p2 species is 
dependent upon conventional PKC isoforms (which require both DAG and Ca2+ for activation).96 
Finally, when attempting to pull-down RGS10 from human platelets with Halo-Gi2, we observed 
some degree of RGS10 phosphorylation in the resting condition not observed previously. The 
reasons for this are not entirely clear, but it could potentially be due to some degree of preactivation 
during the preparation of the platelets or phosphorylation of RGS10 following lysis of platelets and 
incubation. However, interestingly, the phosphorylated species in the resting platelets appears to 
be the p1 species, which is not precipitated by Halo-Gi2 in the presence of GDP + AlF4- (to mimic 
the transition state). Conversely, thrombin stimulated platelet lysate leads to the presence of both 
p1 and p2 species but only the p2 species appears to be precipitated by Halo-Gi2 This could imply 
that the p1 species cannot interact with Gi2 while the p2 species can Whether p1 phosphorylation 
directly interrupts interactions or enhances interactions with inhibitory molecules, like SPL and 14-
3-3, while p2 phosphorylation directly enhances interactions or disrupts those with inhibitory 
molecules will require further investigation.  
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CHAPTER 3: RGS10 and RGS18 Differentially Regulate Platelet Biology 
3.1 Introduction 
 While deletion of single RGS proteins has provided evidence for their individual roles, 
questions remain as to the net contributions of RGS proteins as a family to the regulation of platelet 
activation during hemostasis and the homeostatic maintenance of platelet counts in circulation. 
Deleting more than 20 canonical RGS proteins in mice simply isn’t feasible and would likely not 
yield viable offspring. And while Gi2 RGS-insensitive variants exist and produce mice that are least 
somewhat viable, identifying functional Gq RGS-insensitive variants in mice has proven more 
difficult (see Chapter 4). Thus, our approach was to focus on the two predominantly expressed and 
common RGS proteins in both human and mouse platelets: RGS10 and RGS18.41-43 We also 
sought to compare single deletions of each protein to the dually deleted mice to better assess the 
individual contributions of each protein. 
 Deleting RGS10 or RGS18 alone has measurable effects, largely consistent with previous 
reports, but the full impact of these proteins can only be appreciated when both are absent. Deleting 
RGS10 has no impact on platelet counts, while deleting RGS18 results in a reduction of ~15%. 
Dual deletion of both RGS10 and RGS18 results in a further decrease in platelet counts of ~40%. 
Platelets from RGS10-/-RGS18-/- (but not RGS10-/- or RGS18-/- mice) exhibit an increased rate of 
clearance from circulation, increased basal surface expression of TLT-1 and increased thiazole 
orange staining. Further, treating RGS10-/-RGS18-/- mice with dual anti-platelet therapy (DAPT) 
consisting of aspirin and P2Y12 ADP receptor antagonist, prasugrel, normalizes their platelet counts 
to levels comparable to RGS18-/- mice, suggesting that their decrease in platelet counts can be 
explained, in part, by premature clearance of hyperactive platelets in circulation. In addition, 
RGS10-/-RGS18-/- and RGS18-/- mice (but not RGS10-/-) exhibit delayed recovery of platelet counts 
after depletion and a trend towards a decreased capacity to produce proplatelets, indicating that 
the remainder of the decrease in platelet count is likely due to defects in platelet production from 
megakaryocytes. Taken together, this data suggests that RGS18 plays a minor role in signaling 
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that promotes platelet production from megakaryocytes, while both proteins combine to attenuate 
aberrant signaling under basal conditions that would otherwise result in platelet activation and 
subsequent clearance. 
 In addition to their roles in regulating platelet lifespan, RGS10 and RGS18 also have a 
significant impact on hemostasis. Responses to platelet activating GPCR agonists ex vivo, 
including PAR4 activating peptide, TP-activating TxA2 mimetic (U46619) and P2Y1- and P2Y12-
activating ADP, are increased for the RGS10-/-RGS18-/- platelets relative to controls.  And while 
previous reports by ourselves (see Chapter 2) and others suggest a modest role in regulating 
hemostatic plug formation and preventing blood loss for RGS10 and RGS18 deletion in 
isolation,62,63 penetrating hemostatic injuries in RGS10-/-RGS18-/- mice evoke a response that is 
significantly exaggerated to the point of vessel occlusion, a rare occurrence in this model. These 
results, taken together with those above, suggest that RGS10 and RGS18 cooperate to attenuate 
signaling under basal and hemostatic conditions to prevent unnecessary clearance and vascular 
occlusion, respectively.  
3.2 Materials and Methods 
3.2.1 RGS10-/- RGS18-/- mouse model 
 Generation of Rgs10/18 double knockout mice using CRISPR-Cas9 genome-editing 
system was performed essentially as described by Henao-Mejia et al97 and all mouse protocols 
and procedures were approved by the Institutional Animal Care and Use Committee of the 
University of Pennsylvania. Briefly, Cas9 mRNA was generated from pMJ920-Cas9 plasmid using 
mMESSAGE mMACHINE T7 Ultra Transcription Kit according to the manufacturer’s instructions 
(Life Technologies, AM1345). The quality of the Cas9 mRNA was determined by analyzing Cas9 
mRNA pre- and post-polyadenylation with a 2100 Bioanalyzer. gRNAs were designed for Rgs10 
and Rgs18 genes by following the protocol described in Ran et al.98 T7 promoter was added to the 
gRNA templates by PCR amplification. The PCR product was purified and then used as a template 
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for in vitro transcription according to the manufacturer’s specifications (MEGAshortscript T7 kit, Life 
Technologies). The gRNAs were then purified using the MEGAclear kit (Life Technologies). gRNA 
quality was verified on agarose gel. Zygotes from C57BL/6 mice were injected with Cas9 mRNA 
(100 ng/µl) and gRNAs (50 ng/µl). Embryos were then transferred to pseudo-pregnant C57BL/6 
females. After birth, 10-day-old mice were tail-snipped and genomic DNA was extracted for 
genotyping and sequencing. The lone founder mouse (Rgs10-/-Rgs18+/-) was backcrossed to 
genetically identical parental WT C57BL/6 mice. Successive breeding with mice from the same 
colony was performed as necessary to generate Rgs10+/+Rgs18+/+, Rgs10-/-Rgs18+/+, 
Rgs10+/+Rgs18-/-, and Rgs10-/-Rgs18-/- mice. Age- and sex-matched WT, single and double 
knockouts for experimental use were generated from homozygous parents for each genotype. 
 
3.2.2 RGS10-/- RGS18-/- genotyping 
Mice were genotyped for Rgs10 using a three primer PCR-based strategy. Forward Primer: 
5’-GTGGATAACAGTCCAGCTTCTC-3’, Reverse Primer 1: 5’-CCAGAGCCCATCTCACATTTA-3’, 
Reverse Primer 2: 5’- GTTCCTCAGCCTTCGTCAAT-3’. P R was performed with the following 
conditions: Denaturation at 95°C for 5 minutes; 35 cycles of (95°C for 30 seconds, 58°C for 30 
seconds, and 72°C for 1 minute); extension at 72°C for 7 minutes. Mice were genotyped for Rgs18 
by P R and endonuclease digestion strategy. Forward Primer: 5’-
TGTGTAAATGTGTGGATCCTTGT-3’, Reverse Primer: 5’-
ACTTTCAATCCATAATCATACGCTGTATTCTG-3’. P R was performed with the following 
conditions: Denaturation at 95°C for 2 minutes; 35 cycles of (95°C for 30 seconds, 59°C for 45 
seconds, and 72°C for 45 seconds); extension at 72°C for 5 minutes. Samples were then incubated 
with ApoI-HF according to manufacturer protocol. Additionally, to routinely verify PCR genotyping 
results, samples were processed with ExoSAP-IT PCR Product Cleanup Reagent (Affymetrix, 
Santa Clara, CA) according to manufacturer protocol prior to addition of Forward Primer for Sanger 
sequencing through the Genomics Analysis Core at the University of Pennsylvania. 
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3.2.3 Preparation of diluted whole blood for flow cytometry 
Whole blood was isolated via the retro-orbital plexus from isoflurane-anesthetized mice 
using heparinized micro-hematocrit capillary tubes. Blood was diluted 1:20 with modified Tyrode’s 
bufffer (137 mM NaCl, 20 mM HEPES, 5.6 mM glucose, 1 g/liter BSA, 1 mM MgCl2, 2.7 mM KCl, 
3.3 mM, NaH2PO4, pH 7.4) and stored at 37°C prior to analysis. 
3.2.4 Flow cytometric analysis of platelet activation 
Diluted whole blood was prepared as outlined in 3.2.3 and incubated with 1 mM aspirin 
and 1 U/mL apyrase for 30 minutes at 37°C to eliminate secondary signaling (except for ADP 
measurements, incubated only with 1 mM aspirin). Following inhibitor treatment, diluted blood was 
treated with agonist for 15 minutes at 37° C in the presence of saturating concentrations of 
fluorescently-labeled mAb against P-selectin, activated IIb3 integrin (Jon/A) and F(ab’)2 fragments 
against CD41 (IIb) and analyzed on a FACSCanto II cell analyzer (BD Biosciences, San Jose, CA). 
The platelet population was gated based on FSC/SSC and CD41 positivity. For thiazole orange 
(TO) studies, platelets were incubated with 1 g/mL of TO for 20 minutes at 37° C prior to staining 
with CD41 (IIb). For TLT-1 studies, platelets were co-incubated with Alexa Fluor 488-labeled mAb 
against TLT-1 in place of P-selectin. 
3.2.5 Platelet and fibrin accumulation following penetrating vascular injury 
Hemostatic thrombus formation was observed in the cremaster muscle microcirculation of 
male mice aged 8-12 weeks, as previously described.78 Briefly, Alexa Fluor 568–labeled anti-CD41 
F(ab’)2 fragments, Alexa Fluor 488–labeled anti–P-selectin, and Alexa Fluor 647-labeled anti-fibrin 
were administered via a catheter in the jugular vein. Arterioles 30-50 µm in diameter were studied. 
Penetrating vascular injuries were produced with a pulsed nitrogen dye laser fired through the 
microscope objective. Thrombus formation was observed for 3 min at 1.9 frames per second and 
analyzed using SlideBook 6 software (Intelligent Imaging Innovations, Denver, CO). Transient 
occlusions were defined as hemostatic thrombi that filled the diameter of the blood vessel, but 
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either did not fully block blood flow or blocked it temporarily. Stable occlusions were defined as fully 
occluded vessels that did not recover flow by the end of the observation period. 
3.2.6 Bone marrow megakaryocyte immunohistochemistry 
Femurs were harvested from mice and fixed for at least 48 hours in 10% neutral buffer 
formalin. Decalcification, paraffin embedding, sectioning and slide mounting was performed by the 
Comparative Pathology Core at the University of Pennsylvania School of Veterinary Medicine. 
Immunohistochemistry to stain for IIb was performed as previously described.99 Briefly, slides were 
incubated with goat anti-human integrin IIb followed by peroxidase-conjugated anti-goat 
secondary, stained with DAB Peroxidase Substrate Kit, and counterstained with hematoxylin. 
Imaging was performed using a 20X objective on a Nikon Eclipse E600 microscope and 
quantification of megakaryocytes performed blinded by counting large, positively stained brown 
cells with multi-lobed nuclei. 
3.2.7 Platelet depletion and recovery 
Twenty-four hours prior to depletion, mouse whole blood was acquired from the retro-
orbital plexus and counted with a Procyte Hematological Analyzer (Idexx Laboratories, Westbrook, 
ME) to establish base-line counts. To assess the rate of platelet production, mice were injected via 
the retro-orbital plexus with 0.2 g/g bodyweight of platelet-depleting rat anti-GPIb antibody 
(Emfret Analytics, Eibelstadt, Germany) multiplied by the percent of platelets relative to Wild type 
(WT) baseline (to account for differences in base-line platelet counts between genotypes). Twenty 
minutes post-injection, platelets counts were <5% of baseline for each genotype. Every 24 hours 
for five days, whole blood was obtained from the retro-orbital plexus and analyzed for platelet 
counts as they recovered. 
3.2.8 Platelet clearance from circulation 
To assess the rate of platelet clearance, mice were injected via the retro-orbital plexus with 
non-saturating concentrations (1 μg/g body weight) of rat anti-GPIb-Dylight488 (Emfret Analytics, 
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Eibelstadt, Germany) to label the existing platelet pool while avoiding excess free antibody in 
circulation. Twenty minutes post-injection, ~90% of CD41(+) platelets were GPIb(+) for each 
genotype as assessed by flow cytometry. The percent of GPIb(+) CD41(+) platelets was then 
tracked every 24 hours for four days to assess the rate of platelet clearance. 
3.2.9 Treatment with dual anti-platelet therapy 
Mice were administered 50 mg/kg of aspirin and 1.875 mg/kg of prasugrel in 0.5% 
methylcellulose via oral gavage daily for 10 days total. Prior to the first dose and every 5 days after, 
blood was obtained via the retro-orbital plexus and platelet counts were determined with a Procyte 
Hematological Analyzer (Idexx Laboratories, Westbrook, ME). 5 days after treatment ceased, 
platelet counts were determined once more as described. 
3.2.10 Megakaryocyte progenitor analysis 
Bone marrow was isolated from femurs and tibias by flushing with PBS + 1X Penicillin-
Streptomycin (Gibco, Waltham, MA) and counted using an automated trypan blue cell counter. To 
quantitate numbers of healthy, immunophenotypic bone marrow megakaryocyte progenitors 
(MegPs), cells were stained with the following fluorescently labeled antibodies: Pacific blue-anti-
mouse lineage cocktail (Lin), PerCP/Cy5.5 anti-Sca-1,  APC/Cy7 anti-c-Kit, PE anti-CD16/CD32,  
PE/Dazzle 594 anti-CD150, FITC anti-CD41, and fluorescent BUV395 Annexin V (to exclude 
apoptotic cells) and analyzed by flow cytometry. Healthy MegPs were defined as Annexin 
V(─)Lin(─)Sca-1(─)c-Kit(+)CD16/32(─)CD150(+)CD41(+) cells. 
3.2.11 Cultured megakaryocyte analysis 
Unfractionated bone marrow cells isolated as outlined above were seeded at 5 x 106 cells 
per well in a 6-well plate in Iscove’s Modified Dulbecco’s Medium (IMDM) containing 10% FBS 
(HyClone, Chicago, IL), 100 U/mL Pen/Strep (Gibco, Waltham, MA), 2 mM Glutamine (Gibco, 
Waltham, MA), and 50 ng/mL mouse thrombopoietin (TPO; R&D Systems, Minneapolis, MN). Cells 
were cultured for 5 days and media was replenished on Day 3 of culture. On Day 5, terminal 
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megakaryocytes (Megs) and Meg ploidy were quantitated by staining with APC anti-mouse CD42d, 
FITC anti-mouse CD41, and Vybrant DyeCycle followed by flow cytometric analysis. Megs were 
defined as CD42d(+)CD41(+) cells and ploidy was determined by measuring distinct histogram peaks 
in DyeCycle within the CD42d(+)CD41(+) subpopulation. Following enrichment via a 1.5%/3% BSA 
gradient, cells were seeded into 24-well plates coated with fibronectin (Thermo Fisher, Waltham, 
MA) and containing 10% FBS, 100 U/mL Pen/Strep, and 10 ng/mL TPO. After 48 hours, cells 
extending at least one proplatelet protrusion were counted and imaged using a phase contrast 
inverted microscope at 200X total magnification attached to an 18 mega pixel digital camera 
(OMAX, Kent, WA).  Three wells were examined per condition and at least 100 cells quantitated 
per well. 
3.2.12 Bone marrow chimeras 
Four days prior to irradiation, mice began treatment ad libitum per os with 
Sulfamethoxazole and Trimethoprim (Aurobindo Pharma, Hyderabad, India) to prevent infections. 
Mice were then irradiated with two doses of 550 rad each spread 2 hours apart. Following 
irradiation, donors were retro-orbitally injected with 2 x 107 unfractionated bone marrow cells in 
sterile DMEM isolated from recipients as outlined above. After reconstitution of bone marrow was 
complete, platelet counts were determined as described, mice were euthanized and their spleens 
were harvested and weighed for analysis. 
3.2.13 Mouse lung immunofluorescence 
Mice were injected with DyLight488-labelled anti-mouse GPIb (Emfret Analytics, 
Eibelstadt, Germany) 24 hours prior to experiment. Three minutes prior to euthanasia, mice were 
either injected with either saline as a vehicle control or 18 μg/mL collagen and 150 μg/mL 
epinephrine to induce systemic thrombosis as a positive control. Following euthanasia, lung was 
harvested, fixed for 24 hours in 4% neutral buffered formalin, cryoprotected with sucrose, and then 
frozen in optimal cutting temperature (O T) compound (Sakura Finetek, Torrance, A). After 5 μm 
sections were cut, samples were mounted with VECTASHIELD Antifade Mounting Medium with 
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DAPI (Vector Labs, Burlingame, CA).  Images were acquired from at least three fields per sample 
using a Nikon Eclipse TE2000-U at 20X magnification equipped with blue (DAPI) and green (FITC) 
filters and analyzed with Slidebook6 software. 
3.3 Results 
3.3.1 RGS18-/- and RGS10-/-18-/- mice have fewer platelets but are otherwise normal 
To generate RGS10-/-18-/- mice via CRISPR-Cas9, two single guide RNAs were designed 
for each gene, each targeting Exon 4 and Intron 4 (Figure 3-1A). Exon 4 encodes part of the RGS 
domain for both proteins. Complete regional deletion within the Rgs10 gene results in loss of 
RGS10 expression (Figure 3-1B left). The same founder possessed a 5 base pair deletion in Exon 
4 of Rgs18, producing a premature stop codon and loss of RGS18 expression (Figure 3-1B right). 
RGS10-/-18-/- mice were viable, grossly normal in appearance and gained weight normally 
compared to age- and sex-matched wild type (WT) controls (Supplemental Figure 3-7A). RGS10-/-
18-/- blood parameters were also normal, except for their platelet counts, which were reduced by 
~40% (Figure 3-1C; Supplemental Figure 3-7B). In agreement with previous reports, RGS10-/- and 
RGS18-/- mice were grossly normal in appearance and did not differ significantly in initial weight 
gains (Supplemental Figure 3-7A).63,100,101 Also consistent with our previous work and reports by 
Delesque-Touchard et al., RGS10-/- mice had normal blood parameters, while RGS18-/- mice had 
a reduction in platelet counts of ~15% (Figure 3-1C).63,101,102 Because of the low probability of 
generating useable genotypes from Rgs10+/-Rgs18+/- parents, breeding was performed with 













Figure 3-1. Generation and characterization of Rgs deletion mice. (A) Graphical 
depiction of Rgs10 and Rgs18 genes. Arrows indicate approximate locations targeted by 
single guide RNAs during CRISPR-Cas9. In both cases, regions within the sequence that 
encode the RGS domain were targeted. (B) Representative RGS10 and RGS18 
immunoblots (top) of platelet lysates from RGS10+/+18+/+ (denoted Wild type) and RGS10-
/-18-/- mice with β-actin (bottom) as the loading control. (C) Platelet counts and mean 
platelet volume of 8-week-old WT, RGS18-/-, RGS10-/- and RGS10-/-18-/- mice. At least 9 




3.3.2 RGS10-/- and RGS18-/- differentially impact GPCR-dependent agonist responses 
 Flow cytometry was used to assess agonist-mediated platelet activation via two 
independent markers: P-selectin, exposed on the platelet surface during  granule 
exocytosis,103,104 and activated IIb3 integrin.105 While there was no difference between resting or 
maximal P-selectin exposure amongst genotypes in response to PAR4 agonist peptide (PAR4P, 
AYPGKF), there was a pronounced leftward shift in the dose/response curve for RGS10-/- and 
RGS10-/-18-/- platelets (E 50 of 78.5 and 73.75 μM, respectively) relative to WT (E 50 of 12  μM), 
indicating an increase in sensitivity.  A smaller but still significant shift was observed for RGS18-/- 
platelets (E 50 of 99. 2 μM; Figure 3-2A; Supplemental Figure 3-8A), suggesting a more limited 
contribution of RGS18 to PAR4 signaling. A nearly identical pattern was observed using the Jon/A 
monoclonal antibody, which recognizes the activated conformation of the integrin IIb3. We 
observed a similar left-shift for both RGS10-/- and RGS10-/-18-/- platelets (EC50 of 89.2 and 83.19 
μM, respectively) with a more moderate shift for RGS18-/- platelets (EC50 of 103.6) (Figure 3-2B; 
Supplemental Figure 3-8B; Supplemental Table 3-1). Compared to the EC50 of wild type controls 
(129.5 μM), this supports the notion that RGS10 plays a more substantial role regulating PAR4 
signaling than RGS18. 
In contrast to our results with PAR4 agonist peptide, RGS10-/- and RGS10-/-18-/- platelets 
showed a marked increase in their maximal P-selectin and integrin activation responses to ADP 
and the TxA2 mimetic, U46619, that was not seen with RGS18-/- platelets (Figure 3-2C-F; 
Supplemental Figure 3-8C-F). This further suggests that RGS18 is contributing minimally (if at all) 







Figure 3-2. RGS10 and RGS18 differentially impact in vitro platelet dose-
responses. Flow cytometric analysis of (A, C, E) P-selectin expression and (B, D, F) 
integrin IIb3 activation of platelets from matched WT, RGS18-/-, RGS10-/-, and RGS10-/-
18-/- mice. Platelets were stimulated with increasing doses of: (A, B) PAR4 activating 
peptide (PAR4P, AYPGKF), (C, D) ADP and (E, F) TxA2 analogue (U46619) and gated by 
FSC/SSC and CD41 positivity. At least 4 measurements were collected per genotype per 





3.3.3 RGS10-/-18-/- results in excessive hemostatic platelet activation and thrombosis 
Platelet function in vivo was assessed with real time intravital confocal fluorescence 
microscopy following a laser-inflicted penetrating injury in cremaster muscle arterioles.78 Because 
the vessel wall is penetrated and blood escapes, we view this as a model of hemostasis, rather 
than thrombosis, and have previously shown that results obtained using a laser are identical to 
those produced with a mechanical puncture. The hemostatic plugs that form in this setting have a 
characteristic architecture in which a densely-packed core of fully-activated, P-selectin(+) platelets 
is overlaid by a shell of loosely-packed, P-selectin(─) platelets.78 We’ve shown that the core is driven 
primarily by high local concentrations of thrombin, which leads to fibrin deposition as well as platelet 
activation, while the shell is less activated and driven mainly by released ADP and TxA2.78,106 
Representative endpoint images of hemostatic plugs formed in WT and RGS10-/-18-/- mice 
3 minutes after injury are shown in Figure 3-3A. Mean platelet accumulation was greater in the 
RGS10-/-18-/- mice than in controls, an increase of 77% (Figure 3-3B, E left; Supplemental Video 
1). Similarly, we see a 111% increase in the area of P-selectin(+) platelets (Figure 3-3C, E middle). 
Further, by subtracting the P-selectin(+) core area from the total platelet area, we can extract the 
area of the P-selectin(─) shell, which was 69% larger in the  RGS10-/-18-/- mice (not shown). 
However, there was no significant difference in the percentage of P-selectin(+) core area between 
genotypes (18% for WT and 22% for RGS10-/-18-/-; not shown). Additionally, the kinetics and extent 
of fibrin accumulation in the RGS10-/-18-/- mice was indistinguishable from the controls, suggesting 
that deleting both RGS proteins does not affect the generation of thrombin (Figure 3-3D, E right). 
Finally, the dramatic increase in platelet accumulation was accompanied by an increase in both 
transient and stable occlusion of the arterioles (Figure 3-3F; Supplemental Video 2), an event rarely 
observed in WT mice in this model. This suggests not only a prominent role for RGS proteins 
regulating the hemostatic response to injury but also a potential role in limiting thrombosis under 






Figure 3-3. RGS10-/-18-/- enhances the in vivo hemostatic response. Real time 
confocal intravital microscopy following penetrating laser injuries in cremaster muscle 
arterioles in WT and RGS10-/-18-/- mice.  (A) Representative endpoint images of hemostatic 
plugs. Platelets (CD41) are labeled red, P-selectin (P-sel) is green, and fibrin is blue. 
Overlay of CD41 and fibrin appears magenta, CD41 and P-selectin appears yellow, fibrin 
and P-selectin appears cyan, and overlay of all three channels appears white. Mean area 
of accumulation for each fluorophore was measured over time: (B) CD41 (IIb integrin), (C) 
P-selectin, and (D) Fibrin. (E) Mean endpoint area calculations for each individual 
fluorophore. (F) The fraction of injuries that produced stable or transient occlusions as 
defined in methods. N = 52 for WT injuries and N = 50 for RGS10-/-18-/- injuries. 




3.3.4 RGS18-/- reduces platelet counts due to decreased production 
Because RGS18-/- and RGS10-/-18-/- mice have reduced platelet counts of 15% and 40% 
of WT controls, respectively, we hypothesized that there may be a defect in platelet production. To 
assess this, we first quantified megakaryocytes in femurs obtained from RGS10-/-, RGS18-/-, 
RGS10-/-18-/- and control mice stained with anti-CD41 and examined by light microscopy. Despite 
the reduction in platelet count in the RGS18-/- and RGS10-/-18-/- mice, megakaryocyte counts were 
normal for all genotypes (Figure 3-4A-B), suggesting that the decrease in platelet count is not 
primarily due decreased megakaryocyte differentiation.  
Next, to assess platelet production, we used a specific GPIb antibody to deplete platelets 
in mice from each genotype and tracked the generation of new platelets over 96 hours. During the 
first 48 hours of this recovery, we saw no significant difference between the knockouts and WT 
controls. However, by 72 hours onward, we observed a delay in recovery for RGS18-/- and RGS10-
/-18-/- mice (Figure 3-4C). While the interpretation of such results is complicated by other factors, 
including concomitant clearance, this could indicate a decreased capacity to produce platelets.  
Finally, we performed an in vitro analysis of megakaryocytes (Megs) to determine their 
capacity to differentiate and/or produce proplatelets. These results suggest a trend towards an 
increase in megakaryocyte progenitors and a decrease in proplatelet potential for RGS18-/- and 
RGS10-/-18-/- Megs, but no difference in the transition from Meg progenitor to Meg or Meg ploidy 
(Supplemental Figure 3-9). Taken together, this suggests that at least some portion of 
thrombocytopenia observed in RGS18-/- and RGS10-/-18-/- mice may be due to decreased platelet 







Figure 3-4. RGS18-/- and RGS10-/-18-/- results in reduced platelet production. 
(A) Cross-sectioned femurs harvested from WT, RGS18-/-, RGS10-/-, and RGS10-/-18-/- 
mice were stained for CD41 (IIb integrin) and counterstained with hematoxylin. Large, 
multinucleate CD41(+) cells were counted as megakaryocytes. White arrows point to 
representative examples. (B) Megakaryocyte counts from five randomly selected fields per 
mouse. N = 3, mean ± SEM. (C) Platelet depletion with an anti-GPIb antibody followed 
by recovery over the course of 96 hours represented as a percentage of the baseline for 
each genotype. ** indicates P ≤ 0.05 for WT vs RGS18-/- and RGS10-/-18-/-. N = 6, 




3.3.5 RGS10-/-18-/- reduces platelet survival and increases preactivation in circulation 
Although both RGS18-/- and RGS10-/-18-/- mice appear to have a reduced platelet 
production potential, RGS10-/- mice do not. We thus hypothesized that the further decrease in 
RGS10-/-18-/- platelet counts may be due to decreased survival in circulation. To assess platelet 
survival, mice of each genotype were injected with non-saturating concentrations of a GPIb 
antibody that has no effect on platelet activation.107 At successive 24-hour intervals, blood was 
drawn and the percentage of remaining anti-GPIb(+) platelets was determined (Figure 3-5A). The 
results show that RGS10-/-18-/- platelets have a significantly reduced survival (t1/2 = 46 hours), 
clearing faster than either the single RGS protein knockouts or controls (t1/2 = ~62 hours). 
Next, we stained resting platelets from each genotype with thiazole orange (TO), which 
binds to RNA. Platelet RNA content declines as platelets age in the circulation, which means that 
TO positivity represents the population of younger platelets.108 The results show that a significantly 
higher proportion of RGS10-/-18-/- platelets were TO(+), when compared to other genotypes (Figure 
3-5B),  suggesting that a larger fraction of RGS10-/-18-/- platelets are younger than single knockouts 
or controls. 
Considering the evidence of increased clearance, we asked whether the hyperreactivity 
we observed in the absence of RGS10 and RGS18 translates into increased spontaneous platelet 
activation in the circulation that may reduce survival. To test this hypothesis, flow cytometry was 
used to detect the binding to freshly isolated platelets of three antibodies: Jon/A, anti-TLT-1, and 
anti-P-selectin. As noted earlier, Jon/A detects the activated conformation of IIb3 and P-selectin 
expression is a marker for -granule secretion. Triggering receptor expressed on myeloid cells 
(TREM)-like transcript-1 (TLT-1) is highly expressed in platelets, at least partially stored in 
−granules and is reported to be an even more sensitive marker of platelet activation than P-
selectin.109,110 Our results show that the binding of Jon/A (Figure 3-5C) and anti-P-selectin 
(Supplemental Figure 3-10A) to resting platelets from the RGS protein knockouts was 
indistinguishable from controls. There was, however, an increase in TLT-1 expression on the 
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RGS10-/-18-/- platelets that was not observed for single knockouts or WT controls (Figure 3-5D), 
suggesting that RGS10-/-18-/- platelets are already partially activated in the circulation.  
To test this conclusion further, we stimulated WT and knockout platelets with epinephrine 
and measured Jon/A binding and anti-P-selectin expression. Epinephrine activates platelet 2A-
adrenergic receptors coupled to the Gi family member, Gz.111 It has been shown that epinephrine 
alone cannot cause platelet activation, but it potentiates activation when added with other platelet 
agonists, particularly those whose receptors couple to Gq.111,112 The results show that epinephrine 
causes an increase in IIb3 activation in RGS10-/- but not RGS18-/- platelets and an even greater 
increase on RGS10-/-18-/- platelets (Figure 3-5E), supporting the conclusion that these platelets are 
already partially activated. There was also a trend towards an increase in P-selectin expression, 














   
   
   
   
   






















Figure 3-5. RGS10-/-18-/- platelets are preactivated with shorter survival. Flow 
cytometry analysis for WT, RGS18-/-, RGS10-/- and RGS10-/-18-/- mice to measure: (A) 
clearance of anti-GPIb:DyLight488 in vivo labeled platelets over the course of 96 hours. 
At baseline and every 24 hours thereafter, platelets were identified using anti-CD41 (IIb 
integrin) and then analyzed for DyLight488(+) by flow cytometry. * indicates P ≤ 0.05 for WT 
vs RGS10-/-18-/-.  N = 5, mean ± SEM; (B) Relative fraction of platelets that were positive 
for both anti-CD41 and thiazole orange (TO). N = 9, mean ± SEM; (C) Jon/A binding to 
resting platelets; (D) anti-TLT-1 binding to resting platelets; and (E) Jon/A binding to 10 μM 




3.3.6 RGS10-/-18-/- platelet preactivation can be reversed by dual antiplatelet therapy 
Due to the observed increase in platelet clearance of RGS10-/-18-/- platelets, we next 
explored potential mechanisms, the first being that loss of RGS10 and RGS18 causes premature 
desialylation of platelets, leading to enhanced clearance by Ashwell-Morell receptors in the liver.113 
However, we found no increase in RCA-I lectin binding to the platelet surface, which normally 
increases when sialylation decreases (Supplemental Figure 3-10C, D).114 We next measured 
Annexin V binding to resting platelets to determine if enhanced phosphatidylserine exposure 
(indicative of apoptosis) is contributing to increased clearance.115,116 No increase was observed 
(Supplemental Figure 3-10E). Third, we sought to determine if splenic sequestration of RGS10-/-
18-/- platelets might explain their decrease in systemic circulation.117 However, we found no 
differences in the spleen to bodyweight ratio for WT -> WT or RGS10-/-18-/- -> WT bone marrow 
chimeras, despite the RGS10-/-18-/- chimeras having similarly reduced platelet counts 
(Supplemental Figure 3-10F, G). Finally, we asked if microvascular thrombosis was the cause of 
reduced platelet survival,118 but we could not detect any GPIb(+) platelet aggregates in the lungs 
of unstimulated RGS10-/-18-/- mice via immunofluorescence (Supplemental Figure 3-11).  
While the precise mechanism of clearance has remained elusive, we hypothesized that it 
was indeed dependent upon GPCR-mediated activation. Therefore, we asked whether 
administration of dual antiplatelet therapy to inhibit ADP responses and TxA2 production would 
improve platelet survival and reduce the degree of thrombocytopenia found in RGS10-/-18-/- mice. 
Platelet counts were measured before, during and after giving mice aspirin and the P2Y12 
antagonist, prasugrel, using a dosing regimen that was sufficient to blunt platelet responses to 
PAR4P and ADP (Supplemental Figure 3-12). While receiving treatment, the RGS10-/-18-/- mice 
showed an increase in their platelet count to levels indistinguishable from RGS18-/- mice but still 
significantly less than RGS10-/- or WT controls. After withdrawing treatment, the platelet counts for 
RGS10-/-18-/- mice fell to pre-treatment levels (Figure 3-6A). Furthermore, both basal TLT-1 
expression on the platelet surface and staining of TO were normalized to levels comparable to WT 
controls during treatment (Figure 3-6B, C). Taken together, these data suggest that premature 
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platelet activation, but not desialylation, apoptosis or spontaneous thrombosis, is a mechanism 






Figure 3-6. Aspirin/prasugrel reverses RGS10-/-18-/- platelet preactivation. (A) 
Platelet counts in WT, RGS18-/-, RGS10-/-, and RGS10-/-18-/- mice treated daily for 10 days 
with 50 mg/kg aspirin (ASA; cyclooxygenase inhibitor) and 1.875 mg/kg prasugrel (pras; 
P2Y12 inhibitor) by oral gavage, followed by 5 days without treatment. N = 4, mean ± SEM. 
  indicates P ≤ 0.05 for WT and RGS10-/- vs RGS18-/- vs RGS10-/-RGS18-/-. # indicates P 
≤ 0.05 for WT and RGS10-/- vs RGS18-/- and RGS10-/-RGS18-/-. Data showing the impact 
of these drugs on platelet activation is included in Supplemental Figure 4. (B, C) Flow 
cytometric analysis of (B) anti-TLT-1 binding and (C) thiazole orange (TO) staining prior to 






Platelets possess multiple receptors and signaling pathways through which they can 
respond to trauma and control bleeding, nearly all of which involve members of the GPCR 
superfamily. While these activating pathways have been mapped in detail, less is known about the 
intrinsic regulatory mechanisms that modulate the platelet signaling network to prevent 
unnecessary or premature platelet activation, which could be especially important in the setting of 
vessel wall disease. Here we sought to understand the collective impact of RGS proteins on platelet 
function, focusing for the first time on the consequences of deleting the two most prominently 
expressed in platelets. Additionally, we sought to extend observations by ourselves102 and 
others63,100,101 on individual knockouts of RGS10 and RGS18 by performing direct comparisons on 
the same background. 
3.4.1 RGS10 and RGS18 differentially impact platelet GPCR signaling networks 
 Our results with single agonist measurements of platelet activation in vitro suggest that 
RGS10 has more pronounced role in regulating thrombin receptor signaling (via Gq/G13-coupled 
PAR4) than RGS18. However, dual deletion of both RGS10 and RGS18 has a response nearly 
identical to RGS10 deletion alone, indicating that the effects of these two RGS proteins are not 
simply additive. Furthermore, responses to ADP (via Gq-coupled P2Y1 and/or Gi2-coupled P2Y12) 
and TxA2 (via Gq/G13-coupled TP) are similar between RGS10 deletion and dual deletion of both 
RGS10 and RGS18, while RGS18 deletion appears to a have a negligible impact. Since canonical 
RGS proteins, like RGS10 and RGS18, only have reported affinity for Gq and Gi  subunits,31 we 
can reasonably assume that the observed differences are not due to RGS interactions with G13. 
Considering this information, simple differences in affinity for Gq and/or Gi subunits also fail to 
adequately explain the differential responses in our results, since RGS18 has a measurable impact 
on PAR4 signaling but not TP signaling (both Gq-coupled).  
 One potential model that might explain these results is that RGS18 has little to no GAP 
activity below a certain threshold of platelet activation (perhaps via post-translational modifications 
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such as phosphorylation, inhibition by scaffold proteins like spinophilin or both). This would explain 
why RGS18 deletion has a negligible impact on weaker platelet activation stimuli like ADP and 
TxA2 but a moderate effect on stronger PAR4 signaling.  
3.4.2 RGS10 and RGS18 restrain hemostatic platelet activation to prevent thrombosis 
 In prior studies, we have shown that penetrating injuries in the cremaster muscle 
microcirculation of mice bearing an RGS-insensitive G184S substitution in Gi2 causes increased 
platelet accumulation within the growing hemostatic mass.119 Similar injuries in RGS10-/- mice also 
result in increased platelet accumulation as well as an increase in platelet activation.102 Here we 
found that, when compared to controls, deleting both RGS10 and RGS18 has a more exaggerated 
effect than either RGS10-/- or Gi2G184S/+. Platelet accumulation and activation in response to 
analogous injuries in RGS10-/-18-/- mice occurred to a greater overall extent, so much so that there 
was an increased frequency of transient or stable occlusion at the site of injury. In contrast, there 
was no increase in fibrin deposition, from which we infer that there was no increase in thrombin 
generation, but rather an increase in thrombin receptor sensitivity. Taken together with the in vitro 
platelet function studies, this suggests that RGS proteins normally restrict platelet activation to 
prevent a response that exceeds that which is required to stem bleeding. Furthermore, although 
not directly tested, our results suggest that RGS proteins may have the beneficial effect of reducing 
the risk of thrombosis in the setting of vascular disease.  
 However, it is not yet clear why the results observed in vivo appear to be additive (and 
even possibly synergistic) while they do not appear this way in vitro. One obvious difference in our 
injury model is that platelets in a growing hemostatic plug experience a much more complex milieu 
of various agonists than can be replicated by single agonist experiments. As previously mentioned, 
RGS18 may not be activated until higher thresholds of platelet activation are achieved. Therefore, 
it is possible that RGS18 is normally activated under in vivo hemostatic conditions while RGS10 is 
constitutively active, which would explain the dramatic increase in platelet accumulation and 
activation and the increased incidence of thrombosis that we see in our injury model for RGS10-/-
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18-/- mice.  Despite the gap in our mechanistic understanding of their individual roles, this 
nonetheless suggests that RGS10 and RGS18 are playing an even more prominent role in a 
hemostatic setting than we could realistically assess in vitro. 
3.4.3 RGS18 promotes platelet production to maintain circulating platelet counts 
 RGS18-/- mice have a 15% reduction in platelet counts, which is consistent with what has 
been previously reported.101 However, our data suggest that this may be explained by reduced 
platelet production and not reduced survival due to premature platelet activation. While numbers of 
Megs in the bone marrow, the capacity for Meg progenitors to differentiate to mature Megs, and 
Meg ploidy were all normal for RGS18-/- and RGS10-/-18-/- mice, we observed a significant delay in 
platelet recovery after depletion and a trend towards a decrease in proplatelet formation from Megs 
in vitro. Furthermore, only RGS10-/-18-/- platelets, and not RGS18-/- platelets, appear to have a 
reduced lifespan.  
The role that GPCR signaling plays in thrombopoiesis remains poorly understood but there 
are a few examples that highlight its importance. Sphingosine 1-phosphate (S1P) is a bioactive 
sphingolipid that acts through sphingosine 1-phosphate GPCRs (S1pr) and is found at high 
concentrations in circulating blood.120 Zhang et al have shown that Gi-coupled S1pr1 is expressed 
on megakaryocytes and plays a prominent role in thrombopoiesis, without impacting 
megakaryocyte differentiation or localization.121 Similarly, the Gi-coupled ADP receptor P2Y13, 
expressed in megakaryocytes but not in platelets, was shown to promote proplatelet 
formation.122,123 Therefore, it seems likely that, generally speaking, Gi signaling in megakaryocytes 
promotes platelet production. However, the predicted effect of RGS18 GAP activity towards Gi 
subunits would be to decrease platelet production (and therefore increase production when RGS18 
is absent). It is therefore unlikely that RGS18 is significantly impacting these pathways via its 
canonical GAP function. The role that Gq signaling plays in thrombopoiesis remains largely 
unexplored. However, transforming growth factor  (TGF) reportedly upregulates calcium 
signaling in megakaryocytes and has been reported to inhibit proplatelet formation.124,125 It is thus 
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possible that Gq signaling in megakaryocytes, which results in intracellular calcium flux as well, 
inhibits proplatelet formation, and that this effect is exaggerated in the absence of RGS18. 
3.4.4 RGS10 and RGS18 cooperate to prevent preactivation and prolong platelet survival 
In C57BL/6 mice, platelets normally circulate approximately 5 days before being cleared.126 
Here we found that, compared to matched controls, RGS10-/-18-/- mice had approximately 40% 
fewer circulating platelets and those platelets had reduced survival in circulation as assessed by 
antibody labelling and clearance. Importantly, clearance studies using antibodies generally 
correlate well with those that rely upon covalent modification using NHS-biotin. In contrast, platelets 
from mice lacking either RGS10 or RGS18 exhibited no reduction in survival.  
Several observations suggest that the decrease in survival of RGS10-/-18-/- platelets is due 
to increased clearance via premature activation. First, the relative percentage of thiazole orange 
(TO) positive platelets was greater in RGS10-/-18-/- mice than in WT controls. Since TO preferentially 
stains younger platelets,108 increased turnover of older platelets would increase the relative 
proportion of newly-formed platelets. Second, RGS10-/-18-/- platelets, and to a lesser extent RGS10-
/- platelets, responded to epinephrine with an increase in Jon/A binding. Since epinephrine does 
not normally elicit a platelet activation response unless co-stimulated with a second agonist,111,112 
this suggests that RGS10-/-18-/- platelets are already weakly activated. However, it is also possible 
that RGS10 deletion directly enhances Gz responses to epinephrine,127 since we see no evidence 
of platelet preactivation in RGS10-/- mice. Third, resting platelets from RGS10-/-18-/- mice have 
increased surface expression of TLT-1, which is thought to be a more sensitive marker for platelet 
activation than Jon/A or anti-P-selectin antibody binding,109 again suggesting that RGS10-/-18-/- 
platelets  are partially activated. Finally, we found that treating RGS10-/-18-/- mice with aspirin and 
prasugrel temporarily restored their platelet counts to levels comparable to RGS18-/-, but not to WT 
or RGS10-/-. Since dual therapy with aspirin and a P2Y12 antagonist is standard of care for patients 
at risk for coronary and cerebral artery thrombosis, it raises questions about whether variability in 
RGS protein levels or availability could lead to variability in the response to these treatments. 
63 
 
Furthermore, we found no evidence for increased apoptosis, desialylation, spontaneous 
thrombosis or splenic sequestration of circulating RGS10-/-18-/- platelets, suggesting an 
undetermined alternative mechanism of platelet clearance. Combined with the results of the in vivo 
hemostatic injury studies, these results suggest that RGS proteins normally help platelets avoid 
inappropriate activation and have a previously unappreciated role in maintaining platelet survival 
in the circulation. 
While not previously recognized for RGS proteins, the phenomenon of shortened platelet 
survival is not unique to Rgs10/18 dual deletion. Other examples that result in platelet hyperactivity 
and shortened platelet survival include deletion of the catalytic subunit for protein kinase A, thus 
ablating its ability to phosphorylate substrates,128  and loss of RASA3 function , which leads to 
increased integrin activation due to an increase in the amount of activated RAP1B.129 This supports 
the notion that platelets are basally stimulated in the circulation and that endogenous regulators of 


















Figure S3-7. Characterization of mice. (A) Initial weight gains of female (left) and 
male (right) WT, RGS18-/-, RGS10-/-, and RGS10-/-18-/- mice. At least 4 
measurements were collected per genotype per day, mean ± SEM. (B) Blood 
counts, hematocrit and hemoglobin of 8-week-old WT, RGS18-/-, RGS10-/-, and 
RGS10-/-18-/- mice. At least 9 measurements were collected per genotype. NS 











Figure S3-8. Pairwise comparisons for in vitro platelet activation. Statistical 
comparisons to WT controls for flow cytometric analysis of (A, C, E) P-selectin 
expression and (B, D, F) integrin IIb3 activation of platelets from matched WT, 
RGS18-/-, RGS10-/-, and RGS10-/-18-/- mice. Platelets were stimulated with 
increasing doses of: (A, B) PAR4 activating peptide (PAR4P, AYPGKF), (C, D) 
ADP and (E, F) TxA2 analogue (U46619) and gated by FSC/SSC and CD41 
positivity. At least 4 measurements were collected per genotype per condition. NS 






Figure S3-9. In vitro analysis of megakaryocytes. (A) Percentage of 
megakaryocyte progenitors (MegPs) in the lineage cocktail(─)Sca-1(─)c-Kit(+), 
CD16/32(─) (L-S-K+C-) subpopulation of bone marrow cells. MegPs were defined as 
CD150(+)CD41(+) cells within the aformentioned subpopulation. (B) Number of 
megakaryocytes (Megs) per unit input of MegP after culturing for 5 days in the 
presence of thrombopoietin (TPO). Megs were defined as CD42d(+) and CD41(+) 
cells. (C) Percentage of TPO-cultured CD42d(+)CD41(+) Megs that are diploid (2N), 
tetraploid (4N) or greater than or equal to octoploid (≥8N) as assessed via DNA 
dye. (D) Percentage of proplatelet-forming cells after BSA-gradient enrichment 
and culture on fibronectin-coated plates. Cells were defined as proplatelet-forming 
if they possessed visible membrane extensions or protrusions. N = 4. All results 






Figure S3-10. Exploring mechanisms of platelet clearance. Flow cytometric 
analysis of: (A, B) P-selectin on (A) resting or (B) epinephrine-stimulated platelets 
from WT, RGS18-/-, RGS10-/-, and RGS10-/-18-/- mice; (C) RCA-I:FITC binding to 
untreated, galactose-blocked, or sialidase-treated WT platelets (N = 3); (D) RCA-
I:FITC binding to WT and RGS10-/-18-/- platelets (N = 6); and (E) Annexin-V:488 
binding to resting or A23187 (calcium ionophore) treated WT and RGS10-/-18-/- 
platelets (N = 3). (F) Platelet counts of lethally irradiated WT mice reconstituted 
with WT (WT -> WT) or RGS10-/-18-/- (RGS10-/-18-/- -> WT) bone marrow as 
compared to global RGS10-/-18-/- mice (N = 4). (G) Spleen weight (in grams) to 
bodyweight ratio of chimeric WT and RGS10-/-18-/- mice (N = 6). All results shown 





















Figure S3-11. Immunofluorescent analysis of pulmonary thrombosis. Mice 
were injected with DyLight488-labelled anti-GPIb antibody 24 hours prior to 
harvesting lung, fixation, sectioning and immunofluorescent staining for DAPI. 
Three minutes prior to euthanizing, mice were either injected with (A, B) vehicle 
control (saline) or ( ) 18 μg/mL collagen and 150 μg/mL epinephrine to induce 
systemic thrombosis as a positive control. Images were acquired from at least 
three fields per sample using a Nikon Eclipse TE2000-U equipped with a blue 
(DAPI) and green (FITC) filters and analyzed with Slidebook6 software. (D) 
Quantification of total GPIb area for each condition. 
 
 
Figure S3-12. Ex vivo effects of aspirin and prasugrel administered in vivo.  Flow 
cytometric analysis of from WT and RGS10-/-18-/- platelets to measure: (A) TLT-1 
exposure on the surface in response to increasing doses of PAR4P; (B, C) Jon/A 
binding in response to ADP. All the mice were given either aspirin plus prasugrel or 
vehicle (0.5% methylcellulose) daily by oral gavage for a total of 5 days prior to 
assessment. † indicates P ≤ 0.05 and   P ≤ 0.01.  N = 4, mean ± SEM. 
 
 
Table S3-1. Jon/A and P-selectin responses to PAR4 activating peptide. A weighted 
four parameter logistic regression was used to estimate the effective concentration of 
agonist that yields 50% of the maximal signal (EC50), the standard error of each 
measurement (SE), and the percent difference relative to the wild type controls (% Diff). 
 
A B  Wild type RGS10  / 18  / 
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CHAPTER 4: RGS-Insensitive Gq Disrupts Signaling in Platelets 
4.1 Introduction 
 The most common method employed thus far to study individual effects of RGS proteins 
in various cell systems involve genetic deletion, either globally or cell specific. However, since most 
cells express several canonical RGS proteins (with described GAP activity towards Gq and/or Gi 
subunits),31 delineating the net effects of all RGS proteins in a particular system would, more often 
than not, prove unreasonably cumbersome. One discovery that has helped circumvent this issue 
are RGS insensitivity mutations in  subunits. Because these mutations lie at the RGS interface, 
they impair interactions with all RGS proteins and thus inhibit RGS-mediated GAP activity.65 
 As outlined in 1.3, one such RGS insensitive mutation was a G184S substitution in the G i2 
 subunit.66 Using this model to probe the effects in platelets, our lab demonstrated hyperactivity 
downstream of Gi2-specific platelet activation pathways,67 highlighting the importance of RGS 
proteins with respect to attenuating platelet activation. In an in vivo hemostatic model, penetrating 
injuries in the cremaster arterioles of Gi2G184S/+ mice resulted in greater platelet accumulation at 
both the peak and the endpoints when compared to respective controls. In addition, aggregometry 
demonstrated enhanced aggregation of Gi2G184S/+ platelets in response to GPCR-stimulating 
agonists ADP, PAR4 activating peptide (AYPGKF), and TxA2 mimetic (U46619) as well as non-
GPCR GPVI-stimulating agonists collagen and convulxin. However, the effects on GPVI agonists 
were no longer significant when secondary signaling via released ADP (and its effects on G i2-
coupled P2Y12 signaling) were inhibited with the P2Y12 antagonist, cangrelor. This serves to 
highlight not only the critical role that RGS regulation of ADP-mediated Gi2 signaling plays in 
primary platelet activation, but also its importance in limiting secondary signaling that further 
enhances platelet activation. Finally, experiments probing intracellular signaling downstream of Gi2 
activation, including ADP-mediated cAMP depression and Akt phosphorylation, demonstrated 
enhanced responses for Gi2G184S/+ platelets, while intracellular calcium mobilization (a Gq-driven 
process) was not significantly different, supporting the notion that the observed effects in vivo and 
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ex vivo were specific to Gi2 signaling. Taken as a whole, these studies suggest that RGS/G i2 
interactions are indeed important for regulating the hemostatic response via attenuation of platelet 
activation. Furthermore, these results likely underestimate the true impact, as only heterozygous 
mice were used, due to the poor survival of homozygous G184S mice. 
 The analogous mammalian RGS-insensitive glycine to serine substitution for Gq (G188S) 
was first described by DiBello et al.68 While the initial mutation was discovered in the homologous 
yeast gene via a large scale screen, the substitution was also made in human Gq Furthermore, 
they demonstrated impaired RGS7-mediated regulation of 5-HT2C receptor signaling in a co-
transfected recombinant Chinese hamster ovary (CHO) cell model, without disrupting Gq-mediated 
calcium mobilization itself. Lastly, they modelled the effects of the analogous substitution in 
Gi1 (G183S) and its interactions with RGS4. Interestingly, their analysis suggests that this 
mutation creates unfavorable electrostatic and steric interactions for G:RGS but not G:G. 
 To explore the impact of RGS-mediated regulation of Gq in platelet activation and 
hemostasis, our lab used CRISPR-Cas9 and homology directed repair to create the G188S 
substitution in mice. Unexpectedly, our phenotypic and biochemical analyses of this model suggest 
that the G188S mutation does indeed disrupt other downstream effectors, like PLC, as well as 
RGS proteins. Additionally, a structural analysis of Gq interactions demonstrates the considerable 
overlap between RGS:Gq and effector:Gq interfaces, particularly at the position 188, indicating 
a potential reason for these unexpected findings. Finally, a predictive analysis was performed to 
determine if any substitutions within Gq would selectively disrupt interactions RGS proteins but 
not effectors, and we propose several candidates for future studies. 
4.2 Materials and Methods 
4.2.1 GqG188S/G188S mouse model 
Generation of mutant mouse line using CRISPR-Cas9 genome-editing system was 
described in detail by Henao-Mejia et al.130 Briefly, Cas9 mRNA was generated from pMJ920-Cas9 
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plasmid using mMESSAGE mMA HINE T7 Ultra Transcription Kit according to the manufacturer’s 
instructions (Life Technologies, AM1345). The quality of the Cas9 mRNA was determined by 
analyzing Cas9 mRNA pre- and postpolyadenylation in a 2100 Bioanalyzer. sgRNA was designed 
by following the protocol described in Ran et al.131  T7 promoter was added to the sgRNA template 
by PCR amplification. The PCR product was purified and then used as a template for in vitro 
transcription according to the manufacturer’s specifications (MEGAshortscript T7 kit, Life 
Technologies). The sgRNA was then purified using the MEGAclear kit (Life Technologies). 
sgRNA’s quality was verified on agarose gel. Single-stranded DNA (ssDNA) oligonucleotides that 
encode the desired G188S mutation was flanked on each side by ~100 bases homologous to the 
sequence surrounding the sgRNA-mediated double-strand break (DSB). The G188S missense 
mutation, encoded by a GGG→TCG change, also adds a diagnostic RsaI restriction digestion site.  
The CCCC, upstream of TCG change, was replaced with ACCA and introduced a silent mutation 
to prevent re-cutting by Cas9 after editing.  Zygotes from C57BL/6 mice were injected with Cas9 
mRNA (100 ng/l), sgRNA (50 ng/l), and 100 ng/l donor ssDNA. Embryos were then transferred 
to pseudo-pregnant C57BL/6 females. After birth, 10-d-old mice were tail-snipped and genomic 
DNA was extracted for genotyping and sequencing. The two founder mice were each bred to the 
F1 generation using C57BL/6 mice for further analysis. All mouse protocols and procedures were 
approved by the Institutional Animal Care and Use Committee of the University of Pennsylvania.  
4.2.2 Flow cytometric analysis of platelet activation 
 Platelet activation was detected as previously described.80 Briefly, heparinized whole 
mouse blood was diluted 1:40 in modified Tyrode’s buffer (137 mM NaCl, 20 mM HEPES, 5.6 mM 
glucose, 1 g/liter BSA, 1 mM MgCl2, 2.7 mM KCl, 3.3 mM, NaH2PO4, pH 7.4) and incubated with 
1mM aspirin and 1U/ml apyrase for 30 mins at 37 0C. The blood was incubated with agonists in 
presence of saturating amounts of fluorophore-conjugated mAbs for 15 min at room temperature 
and analyzed on a FACSCanto II (BD Biosciences, San Jose, CA). The platelet population was 
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gated based on FSC/SSC and CD41 positivity. For activation studies with ADP, platelets were 
incubated with 1mM aspirin alone. 
4.2.3 Light transmission aggregometry 
 Blood was drawn from the inferior vena cava of anesthetized mice (100:10:3 mg/kg of 
ketamine/xylazine/acepromazine) using a heparinized syringe (150 U/ml, 1:9 dilution with blood).  
Blood was diluted 1:1 with Tyrode’s buffer, and spun at 129 x g for 7 min to prepare platelet-rich 
plasma (PRP). Platelet counts (Beckman-Coulter Z1) were adjusted to 2.5x108/ml. Aggregation was 
observed in a dual-channel Chrono-log lumi-aggregometer. For experiments that focused on shape 
change, platelets were preincubated for 1 min with Integrilin (10 µM) prior to addition of the agonist. 
4.2.4 Intracellular calcium mobilization 
 Calcium measurements were performed as described.102 Briefly, isolated platelets were 
suspended in Tyrode’s buffer without Ca2+ and loaded with fura-2/AM (5 μM) in the presence of 
Pluronic F-127 (0.2 μg/mL) for 20 minutes at 37 ° . The platelets were then washed and 
resuspended in Tyrode’s buffer with no extracellular  a2+.  Changes in fura-2 fluorescence were 
detected with an SLM/Aminco AB2 spectrophotometer, exciting at 340 and 380 nm, and measuring 
emission at 510 nm.  
4.2.5 Hemostatic vascular injury model 
Hemostatic thrombus formation was observed in the cremaster muscle microcirculation of 
male mice age 8-12 weeks as previously described.132 Briefly, Alexa Fluor 568-labeled anti-CD41 
antibody F(ab)2 fragments and Alexa Fluor 647-labeled anti-P-selectin antibodies were 
administered via a catheter in the jugular vein. Arterioles 30–50 μm in diameter were studied. 
Vascular injury was induced using a pulsed nitrogen dye laser fired through the microscope 
objective. Thrombus formation was observed for 3 min at 1.9 frames/sec and analyzed using 
SlideBook 6 Software (Intelligent Imaging Innovations, Denver, CO).  
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4.2.6 Pull-down of Flag-tagged PLC 
Flag-PL β fusion protein was harvested from Flag-PL β3 transfected HEK293 cells and 
then purified using ThermoFisher Scientific Pierce Anti-DYKDDDDK affinity resin kit (Thermo 
Fisher, Waltham, MA).  Mouse platelets were lysed and then incubated with 100 μM GDP as a 
control or 100 μM GDP + AlF4- (10 mM NaF and 30 μM Al l3).  Lysates were incubated with 
activated Flag-PL β-bound resin beads overnight. After 3 washes with lysis buffer, bound proteins 
were subjected to SDS-PAGE and blotted with an anti-Gq, anti-Gi2 or anti-Flag antibody. 
4.2.7 Immunoblotting of platelet lysate 
Platelets were lysed in NP-40 (50 mM Tris, 150 mM NaCl, 2mM EDTA, 1mM EGTA, 1% 
NP40, pH 7.4) or Triton X-100 lysis buffer (50 mM Tris-HCl, 100 mM NaCl, 5 mM EDTA, 1% Triton 
X-100, pH 7.4) in the presence of protease inhibitors. The lysates were boiled in sample buffer 
before sulfate-polyacrylamide gel electrophoresis (SDS PAGE) analysis. Binding of the primary 
antibodies was detected using HRP-conjugated secondary antibodies and the ECL-system 
(Amersham Biosciences). Individual bands were quantified by densitometry and analyzed using 
ImageJ software (NIH). 
4.2.7 Structural and predictive mutation analysis 
The interaction interface of Gq and its known in vivo binding partners (GRK2,133 PLC-3,134 
G1,135 RGS18,136 RGS2,137 RGS10,47 and RGS8138) was predicted using the Robetta 
Computational Interface Alanine Scanning Server139 and existing structures available from the 
RCSB Protein Data Bank140 (www.rcsb.org). An interface residue was defined as having at least 
one atom within a 4 Å radius from another atom in the binding partner and to be significantly buried 
upon complex formation141. Residues predicted to be critical to binding were identified as those 
with the greatest calculated change in binding free energy (ΔΔG) upon alanine mutation141. 
Structures were viewed and the interfaces manually mapped using PyMOL (The PyMOL Molecular 
Graphics System, Version 1.7 Schrödinger, LLC.). Because no structure of RGS18 or RGS10 in 
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complex with Gq exists, the structures were aligned with the analogous RGS8 protein (in complex 
with Gq) using PyMOL prior to performing calculations. To predict mutations that were likely to 
impair RGS interactions but not effector interactions, the aforementioned structures were analyzed 
using a systematic mutational scanning cutoff matrix (mSCM) method.142 The average ΔΔG for 
effector proteins was subtracted from the average ΔΔG for RGS proteins to generate a relative 
“RGS specificity score”. Scores above the arbitrary threshold of 0.4 were selected as candidates 
for RGS insensitive mutations. 
4.3 Results 
4.3.1 GqG188S/G188S impairs survival and growth but not hematopoiesis  
 To understand how an RGS-insensitive mutation in Gq mutation affects platelet signaling 
and its function in vitro and in vivo, mice bearing the G188S mutation in exon 4 of Gq were 
generated using the CRISPR-Cas9 genome-editing approach (Figure 4-1A). Mice heterozygous 
for the mutation (G188S/+) were born in expected Mendelian ratios and developed normally. In 
contrast, only 7.2% of mice homozygous for the mutation (G188S/G188S) could survive after birth 
(Supplemental Figure 4-7). Furthermore, GqG188S/G188S mice were drastically smaller at birth 
(Figure 4-1B) and exhibited markedly reduced weight gains (Figure 4-1C) as compared to their wild 
type (WT) control counterparts. Platelet counts, mean platelet volume and other hematological 
parameters were normal in GqG188S/G188S mice, indicating that the mutation did not affect 





Figure 4-1. Generation and characterization of GqG188S/G188S mice. (A) Strategy 
for introducing G188S substitution by CRISPR-Cas9 via homology-directed repair. 
(B) Representative images of WT and GqG188S/G188S embryos. (C) Weight gains of WT, 





4.3.2 GqG188S/G188S platelet activation ex vivo is drastically attenuated 
 Next, to test the direct effects of the homozygous G188S substitution, flow cytometric 
analysis was performed on isolated platelets to measure activation markers, including integrin IIb3 
activation (Jon/A antibody) and P-selectin exposure (measure of  granule release). While integrin 
activation of GqG188S/G188S platelets was normal in response to the non-GPCR glycoprotein VI 
(GPVI) agonist, convulxin, the response was significantly attenuated for all the GPCR-stimulating 
agonists: ADP, PAR4 agonist peptide (PAR4P; AYPGKF), and the stable thromboxane A2 
analogue, U46619 (Figure 4-2A). The same pattern was also observed for P-selectin, although as 
a less sensitive measure of platelet activation, weaker stimuli like U46619 and ADP were not able 
to elicit a significant degranulation response and were thus not significantly different (Figure 4-2B). 
 Figure 4-2. Gq
G188S/G188S platelets are hyposensitive to GPCR agonists. (A, B) 
Platelets from GqG188S/G188S mice and littermate controls (WT) were stained with 
fluorescently labelled antibodies specific to (A) activated IIb3 integrin (Jon/A) or (B) P-























































4.3.3 GqG188S/G188S platelet aggregation and accumulation is reduced ex vivo and in vivo 
 Because our hypothesis was that the G188S substitution would impair RGS binding, and 
thus enhance Gq signaling and subsequent activation, our flow cytometry results were unexpected. 
To determine whether this apparent attenuated signaling via flow cytometry was anomalous, we 
next measured the functional consequences of the substitution with respect to aggregation ex vivo 
and platelet accumulation in response to injury in vivo. Consistent with the flow cytometric results, 
platelet aggregation in response to 100 μM PAR4P, 10 μM U4  19, and 10 μM ADP was 
dramatically impaired for GqG188S/G188S platelets (Figure 4-3A-C). In contrast, platelet aggregation 
was normal in response to 0.1 μg/mL convulxin (Figure 4-3D).  Furthermore, platelet accumulation 
following a penetrating laser injury in vivo (assessed with fluorescently labelled anti-CD41/llb 
antibody and intravital microscopy) was almost completely abolished for GqG188S/G188S mice. Taken 
together, these results suggest that platelet activation and hemostatic function are drastically 










Figure 4-3. GqG188S/G188S platelets have reduced function ex vivo and in vitro. 
(A-D) Platelet function was assessed via light transmission aggregometry in 
response to (A) 100 μM PAR4P, (B) 10 μM TxA2 analogue (U4  19), ( ) 10 μM 
ADP and (D) 0.1 μg/mL convulxin ( VX); N = 3. (E) Mean  D41 (platelet) area in 
response to hemostatic penetrating laser injury as assessed by intravital confocal 






4.3.4 GqG188S/G188S calcium mobilization is significantly decreased ex vivo 
 From our previous results, the G188S substitution in Gq appears to result in drastically 
impaired GPCR-mediated platelet activation. As mentioned in 1.2, stimulation of Gq-coupled 
receptors leads to activation of PLC, which in turn generates IP3 and DAG from PIP2. IP3 stimulates 
the release of intracellular calcium from stores in the dense tubular system of platelets, where it 
acts as a potent secondary signaling molecule to mediate various platelet activation events. 
Therefore, to determine if the observed defect in GPCR signaling is a result of impaired Gq signaling 
specifically, we measured calcium mobilization in platelets with a cell-permeable ratiometric 
calcium-sensing dye, fura-2. In response to maximal concentrations of PAR4P, ADP and U46619, 
calcium mobilization was dramatically reduced in GqG188S/G188S platelets (Figure 4-4A-D), 
confirming the notion that Gq signaling is impaired by the G188S substitution. 
 
 
Figure 4-4. GqG188S/G188S impairs calcium mobilization. Isolated platelets from 
GqG188S/G188S and WT controls were loaded with fura-2AM and stimulated with 
agonist in the absence of extracellular calcium. Shown are representative traces 
in response to (A) 500 μM PAR4 agonist peptide (PAR4P), (B) 10 μM thromboxane 
A2 analogue (U4  19), and ( ) 10 μM ADP. Arrows indicate addition of agonist. 





4.3.5 GqG188S disrupts RGS and PLC binding  u  d    ’  impact protein expression 
 Because our body of evidence strongly suggests a defect in Gq signaling, we next asked 
whether protein expression was affected by the G188S substitution. Using an anti-Gq antibody to 
immunoblot platelet lysate, we did not observe any obvious decrease in Gq protein expression, 
suggesting that the protein is being translated normally and that it is at least as stable as WT 
Gq (Figure 4-5A) Another possible explanation for the defect in Gq signaling is that an off-target 
mutation has reduced expression of important signaling molecules downstream of Gq. Since PLC3 
is highly expressed in mouse platelets and critical for Gq signaling,143 we immunoblotted for this 
protein as well. Similarly, no defect in PLC3 expression was observed (Figure 4-5B), further 
indicating that decreased protein expression is not likely to explain the defect in Gq signaling. Next, 
we wanted to confirm that the G188S mutation does indeed impair (rather than enhance) binding 
of RGS proteins. To do this, a GST-RGS18 fusion protein was used as bait in a pull-down assay of 
platelet lysate from WT and GqG188S/G188S mice in the presence of GDP and AlF4- to mimic the high 
affinity  subunit transition state. As expected, wild type Gq, but not GqG188S, was precipitated by 
GST-RGS18 under these conditions (Figure 4-5C), confirming that RGS binding is indeed impaired 
by the G188S substitution. Finally, we sought determine whether PLC3 binding, required for Gq 
signaling, was impaired by the G188S substitution. Using flag-tagged recombinant PLC3 as bait, 
a pull-down assay was performed once more with platelet lysate. Only wild type Gq, but not 
GqG188S, was able to be precipitated by PLC3 (Figure 4-5D), suggesting that both RGS and PLC 
binding was disrupted by the G188S substitution. These results, in combination with those 
presented previously, indicate that GqG188S/G188S mouse platelets are defective in Gq signaling 











Figure 4-5. GqG188S/G188S disrupts RGS and PLC binding. (A, B) Immunoblotting 
of WT, GqG188S/+, or GqG188S/G188S mouse platelet lysate with antibodies directed to 
(A) Gq and (B) PLC3 and reprobing for actin as a loading control. (C, D) Pull-down 
assays of WT or GqG188S/G188S mouse platelet lysate, using as bait (C) GST-RGS18 or (D) 
Flag-PLC3. In addition to probing with antibodies against the bait protein, each blot was 





4.3.6 RGS and effector binding interfaces of Gq overlap at G188S  
 Because the G188S substitution appears to impair binding of RGS proteins as well as 
effectors, primarily PLC, we next employed a structural analysis to understand why this might be 
the case. First, various crystal and solution structure models were collected from the RCSB Protein 
Data Bank.140 (www.rcsb.org).  For RGS proteins, we relied upon x-ray crystal structures of RGS2 
and RGS8 in complex with Gq RGS10 in complex with Gi3 and a solution NMR structure of 
RGS18. For effectors, we used x-ray structures of PLC G1 and GRK2 all in complex with 
Gq Since no native structures of RGS10 and RGS18 in complex with Gq exist, both were aligned 
with RGS8 using PyMol prior to analysis (The PyMOL Molecular Graphics System, Version 1.7 
Schrödinger, LLC.). Next, each Gq:protein-of-interest (POI) pair was analyzed using the Robetta 
Computational Interface Alanine Scanning Server to predict which residues, if mutated to alanine, 
would have the greatest impact on binding energetics. The residues with the greatest change in 
binding free energy (ΔΔG) and thus predicted to be most disruptive, were then mapped to the 
surface of Gq using PyMol. As shown in Figure 4-6, the G188S substitution lies in a region where 
the binding interface of RGS proteins and PLC overlap considerably. This explains why the 
change in electrostatic and steric properties of this residue would disrupt not only RGS binding, but 
also PLC binding. Furthermore, this analysis indicates that the binding interface of RGS proteins 
is relatively small and overlaps almost entirely with other effectors, namely PLC Because of this 
overlap, identifying residues that would clearly disrupt RGS binding but not effector binding may be 
difficult. Nonetheless, we attempted to do so in a systematic, unbiased manner using a mutational 
scanning cutoff matrix (mSCM) method.142 The analysis was performed for each of the Gq:POI 
pairs to substitute every possible residue at positions of Gq predicted to be destabilizing for RGS 
interactions by alanine scanning.  The predicted ΔΔG for each mutation was then averaged 
amongst RGS proteins and effectors before computing the difference between the two. The 
resulting “RGS specificity score” provided us with a metric for mutations that were more likely to 
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disrupt RGS binding while not impacting effector binding (Table 4-1). An arbitrary cutoff of 0.4 was 
used to propose viable candidate RGS insensitive mutations for future testing. 
 
  Figure 4-6. Predicted RGS and effector binding interfaces with Gq overlap. 
(A, B) Structures of Gq complexes were aligned to Gq (3AH8) and subject to 
Robetta Computational Alanine Scanning to determine residues that are likely 
critical for intermolecular interactions.  Gq (green) binding partners were 
categorized as effectors  [GRK2 (2BCJ), PLCβ3 (3OHM), and Gβ1 (3AH8)] and 
their interfaces displayed as red, or regulators of G protein signaling [RGS8 
(5DO9), RGS2 (4EKC), RGS10 (2IHB) and RGS18 (2OWI)] and their interfaces 
displayed as yellow. The overlapping interfaces of RGS and effectors are shown 
in orange. The location of the G188S mutation is shown in purple and the predicted 
location of the plasma membrane shown in grey. The structure shown in (B) is the 













 Studies employing RGS insensitive substitutions in Gi2 have proven useful in 
understanding how regulation of this G protein impacts platelet activation and function in vitro and 
in vivo. Since canonical RGS proteins, such as platelet RGS10 and RGS18, specifically interact 
with Gi and Gq  subunits, exploring the effects of an RGS insensitive substitution in Gq was a 
logical step forward to expand our knowledge of RGS-mediated regulation of platelets. 
Furthermore, earlier studies by DiBello et al suggested that a mutation (G188S) analogous to the 
one we had previously studied for Gi2 (G184S) similarly impacted only RGS interactions without 
interrupting downstream signaling.68 However, our results suggest that the G188S mutation in a 
mouse model does not phenocopy what was described in their recombinant cell-based system. 
Platelet activation responses as assessed by flow cytometry were dramatically impaired ex vivo for 
GPCR-stimulating agonists but not GPVI-stimulating convulxin. Functionally, this resulted in 
Table 4-1. Identification of candidate RGS insensitive Gq mutations. Systematic 
cutoff scanning matrix was used to calculate the change in binding free energy (ΔΔG) 
between RGS (yellow) or effectors (red) and Gq for various single amino acid 
substitutions at positions that were predicted by alanine scanning to impact RGS binding. 
The difference between the average ΔΔG for RGS and effectors was calculated to 
generate an “RGS specificity score”. A larger differential (darker green) is indicative of a 
mutation that is more likely to impair RGS binding while minimally impacting effector 





dramatically reduced platelet aggregation in response to the same agonists and impaired platelet 
accumulation in response to in vivo hemostatic injuries. Interestingly, this very nearly phenocopies 
the Gq-/- mice described by Offermans et al.144  Dramatically decreased calcium mobilization 
responses and decreased binding of PLC3 confirmed the notion that Gq signaling was indeed 
impaired by the G188S substitution. Taken together, this would suggest that the G188S mutation 
is not specific to RGS insensitivity and results in functionally deficient Gq. 
 Mouse and human Gq proteins are nearly 100% identical, differing by only a single amino 
acid, so unexpected differences between the two proteins are unlikely to explain why our results 
differ from those described previously by DiBello et al. However, their experiments with human 
Gq were performed in Chinese hamster ovary cells, relying upon endogenous PLC to generate 
DAG and IP3. Mouse PLC3 differs considerably from Chinese hamster PLC3 (~40% identity). 
Thus, it is possible that Chinese hamster PLC can interact with GqG188S normally while mouse 
PLC cannot.  
Our structural analysis supports the conclusion that PLC3 (and possibly other PLC 
isoforms as well) is impaired by the G188S mutation. As we have shown, the substitution resides 
at an overlapping interface between RGS proteins and effectors, PLC3 in particular. The amino 
acid substitution from glycine to a serine not only creates the possibility of steric clash because 
serine is larger, but also electrostatic repulsion because its hydroxyl group has a partial negative 
charge. And although we have relied upon human PLC3 for this analysis, it is ~92% homologous 
to mouse PLC3, making it unlikely they would have drastically different intermolecular contacts 
with highly homologous Gq. Therefore, it seems quite likely that the mutation similarly disrupts 
both RGS and PLC interactions. 
Because of the considerable overlap between the RGS and effector binding interfaces of 
Gq, identifying specific RGS insensitive residues has proven challenging. However, using a 
predictive systematic mutational cutoff scanning matrix method, we have identified mutations that 
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are more likely to specifically disrupt RGS interactions, without impacting effectors. Testing the 
functional consequences of these mutations should form the basis of future studies. 














Figure S4-7. Chi square analysis of observed vs expected Gq genotypes. A total 
of 125 mice that survived birth from hemizygous breeding pairs were genotyped for 
analysis. Of the total, 41 mice were homozygous wild type, 75 mice were hemizygous for 
the G188S allele and 9 were homozygous for the G188S allele. A Chi -square analysis 
of observed (left) vs expected (right) genotypes resulted in a P-value less than 0.0001, 
indicating that the observed results were significantly different than expected according 





CHAPTER 5: Human RGS10 and RGS18 Variants and Platelet Function 
5.1 Introduction 
 To date, our studies on RGS-mediated regulation of platelet function and physiology have 
been limited to mouse models. This is in large part due to a lack of suitable in vitro cell models 
(anucleate platelets cannot be cultured) and specific pharmacological inhibitors (while inhibitors 
have been identified, they are relatively non-specific or lack potency towards platelet RGS10 and 
RGS18).145,146 Furthermore, routine scanning of public genomic databases indicate that loss of 
function mutations in RGS10 and RGS18, the two highest expressing RGS proteins in human 
platelets, are quite rare. This is possibly because mutations are not well tolerated due their relative 
physiological importance. Lastly, no genome wide association studies have yet identified any strong 
associations between RGS10 or RGS18 single nucleotide variants and disease phenotypes that 
we might expect from platelet hyperactivity, such as thrombosis. However, since these studies 
skew heavily towards common variants rather than rare variants, it is not surprising that rarer 
variants of RGS10 and RGS18 are typically below the threshold of statistical significance. 
 Despite the difficulties that have arisen in establishing humanized models for RGS function 
in platelets, it is nonetheless important to extend our understanding beyond the observations that 
have been made with mice. While RGS10 and RGS18 are the two highest expressed RGS proteins 
in both human and mouse platelets, predicted expression levels differ considerably between mice 
and humans. In mice, the estimated copy number per platelet for RGS10 is ~45,000, more than 
double that of RGS18 at ~20,000 (Figure 5-1A).41 In stark contrast, the estimated copy number per 
platelet of RGS10 and RGS18 in human platelets are similar to one another, but much lower at 
~4,500 (Figure 5-1B).43 While it is possible that RGS proteins simply aren’t as important for 
regulating human platelet function, it is equally likely that less is required because they are more 
potent or less subject to negative regulation. Thus, being able to probe the function of RGS proteins 
in human platelets would provide valuable insights into their relative importance. 
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 The Penn Medicine Biobank (PMBB) has provided us with an opportunity to address these 
questions. The PMBB is a healthcare-based biorepository that recruits participants in a largely 
disease-agnostic manner from the entire Penn Medicine Health System, obtains biospecimens for 
research purposes, and consents participants for genomic analyses, permission to access 
electronic health record (EHR) data, and permission to recontact.  Approximately 60,000 adult 
participants have been recruited as of November 2018. Of these approximately 67% are 
white/Caucasian, 25% are African-American, 3% are multiple races, 2% are Asian and 0.1% are 
native American. 50.4% are men. 25% are 18-40 years old, 34% are 41-60 years old, 23% are 61-
70, and 17% are over 70. The PMBB continues recruiting approximately 15,000 participants 
annually, with plans for substantial expansion. Biospecimens include whole blood, serum, plasma, 
enriched cellular fractions, and selected tissues. To date, genome-wide genotype data has been 
generated on ~30,000 participants and whole exome sequencing has been completed on ~20,000. 
Using this genomic data, we have identified seven exonic variants in RGS10 and nine in RGS18 
that are predicted to cause either a missense mutation, a frameshift, or a premature truncation. By 
recalling these patients to acquire blood samples, we hope to establish a correlation between RGS 
protein levels/function and platelet hemostatic reactivity. 
 
  
Figure 5-1. RGS10 and RGS18 are the highest expressed RGS in platelets. 
(A, B) Estimated copy numbers per platelet of RGS proteins identified in 






5.2 Materials and Methods 
5.2.1 Identification of exonic variants in RGS10 and RGS18 
 All whole exome sequenced patients in the Penn Medicine Biobank (PMBB) were queried 
to select potential exonic loss of function (LoF) mutations. Potential LoF variants were defined as: 
1) nonsynonymous single nucleotide variants that cause a subsequent missense mutation 
(missense), 2) insertions or deletions that result in a frameshift introducing a premature stop codon 
(frameshift), or 3) single nucleotide variants that introduce a premature stop codon (stopgain). 
5.2.2 Filtering predicted loss-of-function (pLoF) exonic variants in RGS10 and RGS18 
 To further predict in an unbiased manner which of these potential LoF mutations would be 
deleterious, each allowable variant was scored using the Rare Exome Variant Ensemble Learner 
(REVEL).147 A REVEL score is between 0 and 1, with a higher score indicating an increased 
likelihood of pathogenicity. Notably, only nonsynonymous single nucleotide variants can be 
analyzed by REVEL, so by default frameshifts and stopgains, as defined in 5.2.1, were considered 
above the cutoff threshold. Graphics representing these variants were generated using the 
Illustrator for Biological Sequences.148 
5.2.3 Structural analysis and predictions for missense mutations 
 Nonsynonymous single nucleotide variants resulting in missense mutations above the 
REVEL score threshold were mapped to the available structures of RGS18136 and RGS1047 and 
then analyzed via the DynaMut algorithm to predict effects on protein stability.149 The results are 
presented as the change in folding free energy (kcal/mol) defined as ΔΔG = ΔGWT - ΔGMut, where 
WT is the native protein and Mut possesses the missense mutation. Next, because RGS18 is only 
available as a non-complexed solution structure, it was aligned with RGS10 in the RGS10:Gi3 
complex structure for protein-protein analysis. The RGS:Gi3 complexes were then subject to 
analysis by mCSM-PPI2 to predict changes in protein-protein affinity.150 The results are presented 
as the change in binding free energy defined as ΔΔGA = ΔGAWT - ΔGAMut, where WT is the native 
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protein and Mut possesses the missense mutation. A negative change in Gibbs free energy (ΔΔG) 
suggests a destabilizing effect of the variant. 
5.3 Results 
5.3.1 Novel pLoF RGS10 and RGS18 variants in the Penn Medicine Biobank 
A search of ~12,000 whole exomes in the Penn Medicine Biobank (PMBB) resulted in the 
identification of 21 unique exonic variants in RGS10 and 40 in RGS18. Of these, 12 for RGS10 and 
30 for RGS18 were defined as potential loss of function (LoF) variants. Of note, all variants were 
present on only a single allele and there were no individuals with variants in both RGS10 and 
RGS18. To further predict which variants were likely to be deleterious to protein function, they were 
scored using REVEL, an ensemble method integrating multiple algorithms to predict the 
pathogenicity of rare missense variants. An arbitrary REVEL score threshold was set for RGS10 
and RGS18. Because RGS10 had a narrower range and lower median REVEL score, mutations 
are predicted to be less tolerated. Therefore, a lower threshold was set at 0.1 to increase sensitivity 
(i.e. ability to detect true positives) at the cost of reducing specificity (i.e. ability to remove true 
negatives). For RGS18, with a wider range and higher median REVEL score indicative of being 
more tolerable to mutations, the threshold was set higher at 0.25, increasing specificity but 
sacrificing some sensitivity. Of the potential LoF variants, 7 for RGS10 and 9 for RGS18 were above 
the preset REVEL score threshold and considered predicted LoF variants (pLoF; Figure 5-2). Some 
of these variants were also detected in the Genome Aggregation Database (GnomAD; 
https://gnomad.broadinstitute.org), which is comprised of 141,546 individuals and contains data on 
125,748 exomes and 15,708 genomes as of September 2019 (Table 5-1).151 
Figure 5-2. pLoF RGS10 and RGS18 variants in Penn Medicine Biobank (on following 
page). Variants were identified based on predicted pathogenicity by REVEL scores >0.1 
for RGS10 and >0.25 for RGS18. Variants are color coded as follows: yellow = missense 
mutation, red = premature stopgain, blue = frameshift insertion, and green = frameshift 
deletion. Circles indicate the direct effect of each variant. Squares indicate the indirect 
effects of frameshift insertions or deletions, for which red text indicates a novel premature 
stopgain. The canonical regulator of G protein signaling (RGS) domain, both sufficient and 







Table 5-1. pLoF RGS10 and RGS18 variants in the Penn Medicine Biobank. 
Variants were included if their REVEL (Rare Exome Variant Ensemble Learner) scores 
were >0.1 for RGS10 (red) and >0.25 for RGS18 (blue). REVEL is an ensemble 
method integrating multiple algorithms to predict the pathogenicity of rare missense 
variants. Scores range from 0 to 1 with higher scores predicted to be more pathogenic. 
16 variants in 101 individuals were identified from a dataset of 11,451 exome-
sequenced individuals. Frequencies are relative to the total Penn Medicine BioBank 
patient population. Allelic frequencies within the Genome Aggregation Database 
(GnomAD;  141,546 individuals comprising 125,748 exomes and 15,708 genomes as 
of September 2019, database is maintained online and publicly available by the Broad 







5.3.2 Common pLoF mutations in RGS10 and RGS18 are ethnically linked 
 A frameshift deletion at serine 16 of RGS18 (S16fs) is present in 42 PMBB patients, nearly 
half of the total number of RGS pLoF variant-harboring patients identified (101 individuals) and at 
a higher frequency than the total GnomAD population (0.36% in PMBB vs 0.09% in GnomAD; Table 
5-1). Interestingly, this variant is observed at a much higher frequency in GnomAD for people of 
Ashkenazi Jewish ancestry (1.93% of Ashkenazi vs 0.09% of the total population). Similarly, an 
arginine to glycine missense mutation at position 45 of RGS18 (R45G) is present in 39 PMBB 
patients, more prevalent than in the total GnomAD population (0.34% in PMBB vs 0.07% in 
GnomAD), and preferentially effects individuals of African descent (0.96% of African vs 0.07% of 
the total population). The remaining non-unique variant is a valine to methionine missense mutation 
at position 52 (V52M) of RGS10 present in 6 PMBB patients (0.052%; Table 5-1). Its frequency is 
slightly lower in the total GnomAD population (0.14%) but considerably higher for individuals of 
East Asian descent (1.91%).  
5.3.3 Missense mutations may disrupt RGS stability and/or RGS:G interactions 
 To further predict how these mutations might alter protein function, we first used DynaMut 
to estimate the change in folding free energy upon mutation of native RGS10 and RGS18 
structures. DynaMut is a method of analyzing and visualizing protein dynamics and stability by 
sampling conformations and measuring vibrational entropy changes.149 Each of the mutations for 
RGS18 was predicted to be destabilizing (-ΔΔG) but to varying degrees (Table 5-2), suggesting a 
potential impact on protein functionality. Interestingly, the missense mutations for RGS10 were 
predicted to be either neutral (ΔΔG ≈0) or stabilizing (+ΔΔG; Table 5-2). Next, we estimated the 
change in binding free energy for a complex consisting of RGS10 or RGS18 and Gi3 using mCSM-
PPI2. mCSM-PPI2 is a machine learning method that utilizes graph-based structural signatures to 
model the effects of mutations on protein-protein interactions.150 Interestingly, all of the missense 
mutations analyzed were predicted to be destabilizing to various degrees except for the arginine to 
















Table 5-2. RGS10 and RGS18 missense mutation predictions. DynaMut was used to 
predict changes in folding free energy as a measure of intrinsic protein stability using 
structures for RGS18 (PDB: 2OWI) and RGS10 in complex with Gi3 (PDB: 2IHB). ΔΔG 
= ΔGWT - ΔGMut, where WT is the wild type residue, Mut is the variant and units are 
kcal/mol. mCSM-PPI2 was used to predict changes in binding free energy as a measure 
of RGS affinity to Gi3. ΔΔGA = ΔGAWT - ΔGAMut, where WT is the wild type residue, Mut 
is the variant and units are also kcal/mol. RGS18, available only as an apo solution 






5.3.4 Structural analysis of mutant RGS stability and/or RGS:G interactions  
Finally, we mapped these mutations the to their available structures to gain better insight 
into the potential effects of the observed mutations. Interestingly, the mutated residue predicted to 
be most destabilizing for RGS18, phenylalanine to isoleucine at position 142 (F142I), is partially 
buried within the protein structure. This suggests that changing the amino acid from a large 
hydrophobic residue to a smaller hydrophobic residue decreases stability, possibly by disrupting 
the proper fold of the native conformation (Figure 5-3A; Table 5-2).  Additionally, the two mutations 
that are predicted to have the largest destabilizing effect on RGS18:Gi3 are at or near to protein-
protein interface (Figure 5-3A; Table 5-2), suggesting direct or indirect impacts on intermolecular 
interactions. In contrast, the most stabilizing residue for native RGS10 is a tyrosine to cysteine 
mutation at position 140 (Y140C). Because this residue is solvent exposed, it suggests that 
mutation from a hydrophobic to nucleophilic residue is more energetically favorable in aqueous 
solution (Figure 5-3B). However, this same mutation is predicted to the most destabilizing for the 
RGS10:Gi3 complex (Table 5-2). This is likely because it also lies at the protein-protein interface 





Figure 5-3. Structural analysis of RGS10 and RGS18 missense variants. Non-
synonymous single nucleotide variants resulting in missense mutations were 
mapped to available structures of RGS10 and RGS18. RGS18 is a solution NMR 
structure not in complex with an  subunit. It was aligned with RGS10: Gi3 using 
PyMol prior to amino acid mapping and analyses. RGS10 is an X-ray structure in 
complex with Gi3. This native structure is missing a flexible region which is 
present in the solution NMR structure of RGS10 not in complex with any  subunits 
and is a site for one of the PMBB variants. This solution structure for RGS10 was 













The PMBB represents a valuable resource for studying relationships between genetics and 
phenotypic traits and the amount of available data continues to grow. Furthermore, the ability to 
recall patients provides additional benefits when studying freshly isolated biospecimens, like 
platelets, is an essential component of a functional analysis. Our search of the whole exome data 
available in the PMBB for RGS10 and RGS18, the two most abundant RGS proteins in human 
platelets,43 resulted in the identification of ~200 unique variants. Of these, we identified 16 exonic 
variants in RGS10 (seven) and RGS18 (nine) in 101 total patients that were predicted to result in 
deleterious missense mutations, frameshifts, or premature stopgains. Additionally, many of these 
variants were identified in large-scale publicly available genetics databases, such as GnomAD, 
providing added information about ethnic prevalence of certain variants. For most missense 
mutations, we used predictive algorithms and available protein structures to provide further 
evidence of their purported functional consequences. Finally, we mapped these mutations to 
RGS:Gi3 complexes to better understand the effects on stability and protein-protein interactions. 
The pLoF variant present in the most PMBB patients (42), a frameshift deletion at S16 of 
RGS18, is predicted to result in the introduction of a premature stop codon at lysine 24 (L24), thus 
truncating the protein (Figure 5-1). Importantly, this truncation would completely disrupt the RGS 
domain, which is both necessary and sufficient for GAP activity towards G  subunits. Because it 
is not a missense mutation, we could not employ our predictive algorithms to estimate stability 
changes. However, we can reasonably assume that loss of the RGS domain would either: a) result 
in protein degradation via improper folding or b) yield a non-functional truncated protein. Perhaps 
most interestingly, this variant is more heavily represented in individuals of Ashkenazi Jewish 
descent relative to the broader population available in GnomAD. While the PMBB does not provide 
population statistics for people of Ashkenazi Jewish ancestry, ~2/3 of patients are Caucasian and 
~90% of the Jewish population of the United States is Ashkenazi in origin,152 so it is reasonable to 
predict that a significant portion of these individuals are of Ashkenazi Jewish descent. Due to 
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distinct religious and cultural practices resulting in patterns of genetic isolation, the Ashkenazi 
Jewish population is one of several groups that have garnered interest from those studying rare 
homozygous mutations.153 Notably, however, none of the individuals in the PMBB are homozygous 
for this variant, which could indicate more modern trends of increased genetic admixture.154 
The second most prevalent pLoF variant that we identified in the PMBB database (39 
patients) is a missense R45G mutation in RGS18. This mutation is more prevalent in individuals of 
African descent than the total GnomAD population and almost ¼ of the total PMBB patient 
population is designated as such. While data suggests that African populations are more genetically 
diverse than non-African populations,155 heterozygous advantage is a well-documented 
phenomenon explaining the increased prevalence of certain deleterious mutations in African 
populations, particularly with respect to malarial resistance and sickle cell disease.156 Similarly, a 
LoF mutation in RGS18 could reasonably provide a selective advantage with respect to malarial 
resistance, as it would be expected to enhance platelet reactivity and platelet granule release, a 
byproduct of platelet activation. Platelet granule release has been implicated as an important 
mechanistic step involved in the platelet-dependent destruction of Plasmodium parasites in 
malaria.157,158 Therefore, it is not unreasonable to postulate that the R45G variant in RGS18 might 
be maintained in areas where malaria incidence is high, even if it could have a negative impact 
under settings of thrombosis. However, it is equally possible that this mutation doesn’t impact 
function at all. R45G is spatially separated from the critical RGS domain and the REVEL score 
prediction of pathogenicity is the lowest of those identified for RGS18 (Table 5-1). Furthermore, we 
could not predict changes in stability because the residue is not present in the available structure. 
This is likely because the residue is not part of the rigid helical bundles that make up the core of 
the RGS protein, but rather resides in what we could predict is a more flexible N-terminal region. 
Of the missense mutations that were present in the available structures, those predicted to 
be the most destabilizing in terms of protein-protein interactions were residues that lie at or near 
the protein-protein interface, as expected. The most destabilizing variant of RGS10, Y140C, 
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replaces a large hydrophobic residue with a polar residue. While this is predicted to disrupt the 
RGS:Gi3 interface, likely due to electrostatic repulsion, it surprisingly is predicted to stabilize the 
native structure of RGS10. This, however, is likely because the hydrophobic residue is exposed to 
aqueous solvent, an energetically unfavorable situation due to the hydrophobic effect, and 
replacing it with a hydrophilic residue relieves this energetic burden. The most destabilizing variant 
for RGS18, K158N, replaces a positively charged residue with a polar, but uncharged, residue. 
This is predicted to be destabilizing for RGS:Gi3 interactions, likely due to reduced electrostatic 
attraction, but also destabilizing for native RGS18, as folding free energy is minimized when 
exposed residues are more highly attracted to water molecules in the assumed aqueous solvent. 
To translate our understanding of RGS-mediated regulation of platelet activation from 
mouse models to humans, we sought to identify variants in RGS10 and RGS18 from genetic data 
of patients enrolled in the Penn Medicine Biobank. After filtering for variants that were predicted to 
be loss of function according to our criteria, 16 variants in 101 patients remained. Finally, using 
computational and structural methods, we predicted the impacts of these variants on protein 
stability and protein-protein interactions where possible. While future studies are necessary (and 
pending) to establish the functional consequences of these mutations, we have laid the groundwork 







CHAPTER 6: Conclusion 
6.1 RGS-mediated regulation of murine and human platelet function 
 Much of what we know about RGS proteins and their role in regulating platelet GPCR 
signaling networks has come from mouse models. Fortunately, the two most abundant RGS 
proteins in both human and mouse platelets are the same: RGS10 and RGS18.41,43 Therefore, our 
lab and others have been able to probe the individual impacts of these proteins in platelet activation 
and physiology by comparing their individual genetic knockouts to wild type controls. Additionally, 
we examined the combined contributions of both RGS10 and RGS18 to platelet activation and 
physiology by generating double knockouts and were able to perform direct comparisons of each 
individual knockout on the same genetic background. From our head to head comparisons, our 
data suggests that RGS10 plays a more prominent role in attenuating platelet GPCR signaling, 
while RGS18 is more important for platelet production from megakaryocytes. However, from our 
double knockout studies, we have shown that both proteins contribute to regulating platelet 
activation, as only the dual deletion mice have platelets that are hyperactive enough to be 
prematurely cleared from circulation and generate occlusive thrombi from hemostatic penetrating 
injuries.  
 While RGS10 and RGS18 are the most abundant RGS in human and mouse platelets as 
identified by transcriptomics and proteomics studies, we cannot rule out the possibility that other 
lower abundance RGS proteins are present and contribute to platelet activation. Indeed, prior 
studies have shown that RGS16 is expressed in both human and mouse platelets and contributes 
to regulating platelet GPCR signaling and hemostasis.159,160 Interestingly, an earlier study had 
shown that RGS16 and RGS18 are both expressed in megakaryocytes but that only RGS16 
specifically regulates stromal-cell-derived factor 1 (SDF-1)-mediated CXC chemokine receptor 4 
(CXCR4) signaling.161 SDF-1 has been shown to promote chemotaxis and migration of 
megakaryocyte progenitors to the junctions between sinusoidal bone marrow endothelial cells, 
thereby supporting the release of proplatelets into the circulation.162 However, SDF-1-mediated 
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CXCR4 signaling and migratory potential decreases as megakaryocytes mature,163 which 
negatively correlates with the increase in RGS16 expression,161 thus suggesting that increasing 
RGS16 levels may serve to negatively regulate CXCR4 signaling during megakaryocyte 
development. While the difference does not reach the threshold of statistical significance, the slight 
increase in platelet counts for RGS16-/- mice supports the notion that RGS16 normally attenuates 
CXCR4 signaling to downregulate megakaryocyte proplatelet formation. Considering this data in 
light of our own, we propose a model in which RGS16 promotes proper localization of immature 
megakaryocytes, RGS18 promotes proplatelet formation, and RGS10 has the most prominent role 
in regulating platelet signaling. However, to reiterate, evidence suggests that RGS18 and RGS16 
still contribute to regulating platelet GPCR signaling networks. Additionally, while mutations in 
RGS2 were reported to result in moderately decreased Gs-mediated signaling in human platelets 
via non-canonical interactions,164 mouse knockout models did not suggest any functional 
consequences with respect to platelet function in hemostasis.165 Finally, while reported at lower 
levels, RGS14 and RGS12 were detected by proteomics studies in mouse platelets,41 while RGS6 
and RGS9 were detected in human platelets.43 Its thus possible that these RGS proteins may 
additionally contribute to regulating megakaryocyte development or platelet function. 
Circumventing the issue of knocking out several RGS genes to probe global RGS 
regulation of specific cell types, RGS-insensitive mutants in G subunits have proven useful in 
some circumstances. Furthermore, the  subunits upon which RGS proteins are predicted to act in   
human platelets, Gi2 and Gq, are nearly identical to those in mouse platelets (98.3% and 99.7% 
sequence identity, respectively). We were previously able to elucidate the impact of RGS-mediated 
Gi2 regulation in platelets using Gi2 G184S RGS-insensitive mice, and found that it significantly 
increased platelet accumulation in response to hemostatic injury primarily via expansion of the P-
selectin(─) shell, but not the P-selectin(+) core.67,78  However, we found that the analogous mutation 
in Gq (G188S) dramatically decreased platelet function, due to drastically attenuated Gq signaling 
caused by disrupted interactions with PLC. Nonetheless, there are valuable lessons to be learned 
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from these studies. First, caution should be taken when attempting to translate results from 
contrived systems in vitro to in vivo models. Second, structural analysis of protein interactions can 
provide predictions to inform decisions regarding mutagenesis. Third, while G i2 and Gq are 
structurally very similar, our results suggest that their interactions with their respective effectors 
differ considerably. Finally, RGS and effector interfaces overlap considerably on the surface of Gq, 
meaning it may be difficult or even impossible to generate an RGS-insensitive but otherwise 
functional Gq subunit. Using predictive algorithms, however, we have identified several viable 
RGS-insensitive candidates for future study. 
Extending the observations made in mouse models to human platelet physiology has 
proven challenging. While we can reasonably predict that RGS10 and RGS18 play a role in human 
megakaryocyte development and/or platelet physiology due to their expression levels, we 
nonetheless have no conclusive evidence to substantiate our hypothesis. Furthermore, no RGS10 
or RGS18 null human patients have been identified to date. To address the role of RGS10 and 
RGS18 in human platelet function we have, however, been able to identify 16 pLoF variants in 
human patients that have submitted samples to the PMBB. In addition, by using a structure-based 
predictive analysis, we have reason to believe that these mutations will indeed affect protein 
function. Our pending plans to recall patients and measure platelet functionality and protein levels 
are discussed in more detail in Chapter 7: Future Directions. 
Our studies into the regulation of platelet GPCR activation have revealed a great deal about 
RGS proteins and their impact on platelet physiology. While evidence suggests that RGS10 
regulates Gi2, Gq, and Gz in platelets to have a more prominent impact on platelet activation 
and hemostatic potential, RGS18 plays a lesser role in this respect (with no apparent impact on 
Gz) but may be important in regulating proplatelet formation from mature megakaryocytes. 
Furthermore, the global impact of RGS-mediated regulation of Gi2 confirms the importance of 
these interactions with respect to regulating platelet function during hemostasis, while the impact 
of RGS-mediated regulation of Gq remains to be determined. Finally, the identification of pLoF 
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RGS10 and RGS18 mutations in human patients has provided fertile ground for future studies 
concerning their contributions to human platelet function. 
6.2 Negative regulators of platelet signaling preserve normal platelet function 
Members of the RGS protein family belong to a broader class of negative regulators of 
platelet signaling that modulate many platelet-dependent processes, including hemostasis and 
thrombosis. Hemostasis and thrombosis are often considered two sides of the same coin; while 
hemostasis involves an appropriate and proportionate response to prevent bleeding via the 
coagulation cascade and platelet aggregation, thrombosis occurs when these processes (via 
acquired or hereditary means) are dysfunctional, often resulting in vascular occlusion. This then 
provides the basis for the prevailing theory as to why negative regulation of platelet activation is 
necessary: while rapid activation is required to prevent blood loss in response to injury, 
unwarranted or excessive platelet activation promotes thrombosis. Our own results with RGS10-/-
18-/- mice support this notion, as the response to hemostatic injury was surprisingly exaggerated to 
the extent that a large proportion of thrombi became occlusive. The fact that similar phenomenon 
is not observed in RGS10-/- mice suggests that a “multiple hit hypothesis”, much as has been 
described for cancer,166 may apply to negative regulators of platelet activation. This would further 
help to explain why such a variety of negative regulators exist: redundancy at multiple levels 
prevents unnecessary activation even if one checkpoint fails. In the case of RGS proteins, RGS10 
and RGS18 appear to be partially redundant with respect to limiting hemostatic platelet activation. 
Only loss of both results in a response dramatic enough to increase the risk of thrombosis. But how 
do other negative regulators compare in terms of their impacts on platelet biology? 
The IP receptor, stimulated by PGI2, couples to Gs and represents an extrinsic regulator 
of platelet activation, as it activates AC to promote cAMP production and PKA activity, known to 
broadly inhibit platelet activation pathways.26 IP receptor deletion in mice does not appear to affect 
hemostatic bleeding times, but it exacerbates thrombosis via a ferric chloride model.167 This differs 
considerably from dual deletion of RGS10 and RGS18, as we do see enhanced effects on 
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hemostasis, and although not directly tested, would expect to see exacerbated thrombosis as well. 
One potential explanation for the difference in hemostatic effects is that Gs-mediated AC activation 
is readily overwhelmed by Gi2-mediated AC inhibition during the hemostatic response. Therefore, 
RGS-dependent Gi2 attenuation might be considered a more robust inhibitor of platelet activation 
than IP-coupled Gs activation. But how, then, might we explain the impact on thrombosis? During 
a puncture-induced hemostatic injury, a pressure drop is created, and platelets accumulate where 
the endothelium is ruptured.168 In contrast, in a ferric chloride model, endothelium may be damaged 
but not necessarily lost,169 and there is no pressure drop. Therefore, soluble PGI2 produced by the 
endothelium may be more protective under these settings because it is more closely localized to 
the site of platelet deposition and can’t be flushed extravascularly via the pressure drop created by 
a physical hole.  
Another extrinsic regulator with a role similar to PGI2 is NO, also produced by endothelial 
cells via endothelial NO synthase (eNOS; NOSIII), that can diffuse across the cell membrane to 
activate soluble guanylyl cyclase (sGC), promoting cGMP production and PKG activity.26 Like PKA, 
PKG is known to phosphorylate numerous targets that mediate inhibition of platelet activation. One 
report suggests that deletion of eNOS in mice, in contrast to IP receptor deletion, results in a 
reduced hemostatic bleeding time indicative of an enhanced platelet activation.170 However, 
another report suggests that eNOS deletion results in a trend towards reduced hemostatic bleeding 
time, but this difference is not statistically significant.171 It is important to note, however, that these 
were slightly different hemostatic models; whereas the former report was using a tail vein puncture 
injury model, the latter relied upon a tail transection model.  It would thus seem likely that the impact 
of NO-mediated platelet inhibition depends upon the size and nature of the hemostatic injury; for a 
smaller injury, like a puncture, NO produced by adjacent endothelial cells is likely still able to diffuse 
into platelets accumulating at the site of injury. For a complete transection, however, there are no 
downstream endothelial cells to produce NO and it might be more readily carried away by higher 
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pressure, reducing its ability to inhibit platelet activation. This highlights the importance of 
interpreting results in light of their experimental context.  
If we compare the results for IP-/- and eNOS-/- mice to our studies, some subtle but intriguing 
conclusions emerge. While not tested directly in our RGS10-/-18-/- mice, we do see a dramatically 
enhanced hemostatic response that would more than likely correspond to a decreased bleeding 
time in a tail-bleeding model. Furthermore, both RGS10-/- and RGS18-/- mice individually have been 
previously shown to have reduced bleeding times in a tail-bleeding model.62,63 While not definitive, 
RGS proteins seem to have a more dramatic impact on hemostatic platelet function than extrinsic 
regulators like PGI2 and NO. However, it seems likely that these interpretations could differ in 
magnitude depending upon the context under which the hemostatic measurements are made. 
Nonetheless, this is not altogether surprising as the two groups of regulators are operating at very 
different stages of hemostatic platelet activation: while the extrinsic regulators are poised to prevent 
platelet activation under basal conditions, RGS proteins are positioned to limit the extent of 
activation once it is under way. 
In addition to these extrinsic negative regulators, there are also additional intrinsic 
regulators.  RASA3, a GTPase activating protein for the small GTPase RAP1, limits the extent of 
platelet aggregation by downregulating RAP1-GTP, which promotes activation of IIb3 integrin. 
Stefanini et al present evidence that RASA3 is normally inhibited by Gi2-mediated PI3K activation 
and that a hypomorphic RASA3 variant with drastically reduced expression and GAP function has 
shortened platelet survival resulting in severe thrombocytopenia.129 This further supports the notion 
that platelets encounter stimulating agonists, in this case ADP, under basal conditions and that 
there are negative regulatory mechanisms in place to prevent preactivation and clearance. The 
authors also present evidence that integrin activation in the hypomorph is enhanced in response to 
ADP, but they do not show the potential hemostatic effects ex vivo or in vivo for the hypomorph in 
isolation. Therefore, it is unclear how this mode of regulation alone impacts hemostatic platelet 
function. We can hypothesize, however, that it would not be as important as RGS proteins, because 
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it is further downstream in the signaling network. Furthermore, its function is downregulated during 
hemostasis, whereas we have no evidence that this is true for RGS proteins. 
As a further confirmation of the importance of regulating ADP-mediated signaling under 
basal and hemostatic conditions, we can examine the ecto-apyrase, CD39. CD39 is expressed on 
the surface of endothelial cells and converts both ATP and ADP to AMP.1 Peripheral platelet counts 
in CD39-/- mice are ~20% lower than controls, but the precise mechanisms of this decrease were 
not determined.172 From our results and those presented previously, though, we can hypothesize 
that excessive ADP in circulation would lead to increased activation of platelets and subsequent 
clearance. However, the degree of thrombocytopenia is far more severe in the RASA3 hypomorph, 
which may suggest that sensitivity to ADP is more critical to regulating platelet survival than 
absolute quantities of ADP. Our own results support this, since platelet counts in the RGS10-/-18-/- 
mice are reduced to a greater degree than CD39-/- mice, and RGS proteins modulate ADP 
sensitivity via regulation of Gq-coupled P2Y1 and Gi2-coupled P2Y12. Paradoxically, bleeding times 
and ferric chloride-induced thrombosis were prolonged in CD39-/- mice, rather than shortened. 
However, the authors present evidence suggesting that this is due to desensitization of P2Y 
receptors in response to constant stimulation, thus effectively reducing ADP-mediated signaling.172 
Therefore, it is readily apparent that careful regulation of ADP-mediated signaling, both intrinsically 
and extrinsically, is important for maintaining normal basal and hemostatic platelet function. 
Clearly, platelets possess numerous negative regulatory mechanisms, operating at various 
stages of platelet activation and having varied impacts on platelet survival, hemostatic potential, 
thrombotic risk. This lends further support to the idea that platelet signaling networks, under normal 
circumstances, are in a delicate balance between activating and inhibitory pathways and that 
perturbing this balance can have dramatic effects. We can only speculate as to why this exquisitely 
sensitive system has evolved, but it is likely due the specific nature of the primary hemostatic role 
of platelets. Under basal conditions, platelets need to constantly patrol the circulation for insults. In 
doing so, they are likely encountering numerous mechanical and biochemical stimuli. Without a 
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variety of negative regulators in place to prevent it, these stimuli would presumably result in platelet 
preactivation and premature clearance. On the other hand, platelets need to be ready to spring into 
action at a moment’s notice to prevent excessive bleeding in response to injury. As such, they need 
to be extremely sensitive to the appropriate stimuli under the proper circumstances to be maximally 
effective. However, in the absence of negative regulators, such as RGS proteins, an excessive 
hemostatic response could quickly turn into pathological thrombosis. Therefore, negative regulators 
of platelet signaling preserve an optimal balance between activation and inhibition, both under 




CHAPTER 7: Future Directions 
7.1 Phosphorylation of RGS10 and effects on GPCR-mediated platelet function 
 Our results suggest that RGS10 is phosphorylated in response to agonist stimulation in 
human platelets and that this phosphorylation may impact interactions with G subunits (see 
Chapter 2). However, we have yet to determine the precise site(s) of phosphorylation or the 
functional impact of these phosphorylation events with respect to platelet function. Efforts to isolate 
substantial quantities of endogenous RGS10 from human platelets using either 
immunoprecipitation or Halo-Gi2 pull down have not proven viable. Furthermore, we have not had 
success detecting agonist-mediated phosphorylation of recombinantly overexpressed RGS10 in 
cultured cell lines. However, we do have evidence to suggest that the kinases responsible for 
phosphorylation may be novel and/or conventional isoforms of protein kinase C. Therefore, it may 
be possible to perform in vitro phosphorylation studies using purified Halo-RGS10 (which we have 
already generated) and one or more of the six PKC isoforms reportedly expressed in human 
platelets.173 However, the main pitfall of this approach is that in the absence of cellular trafficking, 
localization, and inhibition mechanisms, phosphorylation may occur indiscriminately and at sites 
that bear no physiological relevance.  
A more complicated, although arguably more robust approach, would involve using 
CRISPR-Cas9 to introduce a purification tag into endogenous RGS10 in human inducible 
pluripotent stem cells (iPSCs).174,175 A tag like SpyTag, engineered by splitting a bacterial 
fibronectin-binding  protein, would be ideal since its small size (13 amino acids) is unlikely to perturb 
protein function and easier to insert via genome-editing techniques, and it covalently binds to its 
bait (133 amino acid SpyCatcher) to allow robust capture and high purity.176 Furthermore, a 
cleavable linker, such as the tobacco etch virus (TEV) protease recognition sequence consisting of 
an additional 7 amino acids, could be appended for elution while minimally increasing the size of 
the tag.177 The iPSCs can then be differentiated into megakaryocytes, induced to generate 
functional platelets, and assessed for agonist-mediated RGS10 phosphorylation as described for 
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patient-isolated platelets.178 Finally, the protein could be isolated using a SpyCatcher-coupled 
substrate, such as magnetic beads, and eluted using TEV protease for mass spectrometry analysis 
to identify the sites of phosphorylation.179 The main limitation of this approach would likely be low 
yields of functional platelets. However, mass spectrometry can be extremely sensitive, requiring 
only femtomolar quantities of protein if sufficiently enriched.180 
Once the phosphorylation sites have been identified, we could similarly employee CRISPR-
Cas9 to mutate phosphorylated residues to either phosphoresistant (such as alanine) or 
phosphomimetic (serine to aspartic acid, for example) residues. Lastly, following generation of 
platelets, we could assess the impact of these mutations on the hemostatic function using flow 
cytometry. An increase in the GPCR-mediated activation response of a phosphoresistant mutant 
would suggest that phosphorylation of that residue inhibits RGS10 function. Conversely, a 
decrease in response would indicate that phosphorylation enhances RGS10 function. Using these 
methods, the nature of RGS10 phosphorylation and the functional consequences could be 
systematically assessed in human platelets. 
7.2 Mechanisms of RGS10-/-RGS18-/- platelet clearance 
 While we have evidence to suggest that platelet clearance in RGS10-/-18-/- mice is a result 
of premature platelet activation in circulation (see Chapter 3), the mechanisms that mediate this 
clearance remain elusive. Annexin V staining was normal for RGS10-/-18-/- mice, suggesting normal 
phosphatidylserine (PS) exposure. During apoptosis, platelets, like many other cells, undergo 
membrane redistribution, whereby PS translocates from the inner to outer membrane.181 Exposed 
PS is a molecular signal for phagocytosis and clearance by macrophages.182 However, annexin V 
may not be the most sensitive marker for smaller changes in PS exposure. Studies suggest that 
lactadherin, a PS-binding protein produced by macrophages, can detect apoptotic cells earlier and 
with more sensitivity than annexin V.183,184 Thus, additional studies to stain RGS10-/-18-/- platelets 
with fluorescently labelled lactadherin may provide evidence of increased apoptosis.  Alternatively, 
it is possible that PS(+) platelets are cleared so rapidly that we are only able to detect the PS(─) 
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RGS10-/-18-/- platelets that remain. To address these concerns, one could specifically deplete 
macrophages in vivo using clodronate liposomes. Clodronate is a hydrophilic bisphosphonate toxic 
to cells in high concentrations and liposomes allow for encapsulation of this molecule for drug 
delivery, where it is subsequently phagocytosed by macrophages.185 Several reports have shown 
improved platelet counts in mice bearing clearance-enhancing mutations,186-188 so it is quite 
possible that this would hold true for RGS10-/-18-/- mice as well. How, though, might these two 
seemingly disparate pathways, platelet activation and apoptosis, be interconnected? One report 
indicates that PKA activity is negatively correlated with apoptosis in platelets.189 Since both Gq 
signaling, via phosphodiesterase activation,190 and Gi2 signaling, via adenylate cyclase inhibition,191 
are both involved in reducing cAMP levels, enhanced signaling in the absence of RGS proteins 
could therefore theoretically reduce PKA activity and promote apoptosis. 
 We have also presented evidence indicating that desialylation, as assessed by the binding 
of RCA-I lectin, was normal in RGS10-/-18-/- mice, suggesting recognition of desialylated platelets 
by hepatic Ashwell-Morell receptors is not likely to explain the reduced survival.192 However, 
desialylated glycans expose -galactose, which can then be removed via -galactosidases to 
expose -N-acetylglucosamine (GlcNAc).193  GlcNAc is recognized by integrin M2 on the 
surface of liver macrophages and leads to phagocytosis and clearance of chilled platelets.194 
Furthermore,  -galactosidases are reportedly stored in platelet granules and mobilized to the 
surface of aged platelets.195 Thus, it is possible that RGS deletion results in enhanced granule 
release, -galactosidase surface expression, GlcNAc exposure and M2-mediated macrophage 
phagocytosis. This would not necessarily be inconsistent with our results, since RCA-I binds 
preferentially to -galactose, but not sialic acid or GlcNAc. Therefore, using a lectin specific to 
GlcNAc could reveal differences between RGS10-/-18-/- and control platelets. And as above, if the 
platelets are being cleared too quickly to detect, clodronate liposomes could be employed in vivo, 
since both processes are similarly macrophage dependent.  
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7.3 Candidate RGS-insensitive Gq mutations 
 Our results suggest that the G188S RGS-insensitive mutation in Gq impacts not only RGS 
interactions and function, but also PLC, the primary Gq effector. We have also shown, using 
structural and computational methods, that the overlap between the binding interfaces of RGS 
proteins and effectors on the surface of Gq is considerable, raising concerns about the viability of 
an RGS-insensitive mutation that maintains primary Gq signaling functionality. However, using a 
systematic predictive approach, we have identified several candidate mutations that are reasonably 
likely to impact RGS interactions without affecting PLC and other effectors (see Chapter 4). How, 
then, might one evaluate these mutations to overcome the limitations of the original recombinant 
CHO-cell based method?  
First, careful consideration should be given to the cell type being used. While CHO cells 
are easily transfected for overexpression of recombinant proteins,196 the expression profile of 
endogenous proteins as well as their exact composition may differ considerably from human (or 
mouse) platelets. Furthermore, the use of cell lines or primary platelets is limited because platelets 
are anucleate and therefore cannot be expanded in cell culture or easily manipulated genetically. 
However, the use of induced pluripotent stem cell (iPSC)-derived megakaryocytes provides a 
promising approach for studying the effects of candidate RGS-insensitive mutations in 
subsequently derived human platelets.178  
The second consideration involves endogenous protein expression. While overexpressing 
proteins is simple and straightforward, it may not accurately reflect the effects of mutation within a 
physiological context. To overcome this, targeting and genetic modification of specific endogenous 
genes can be employed, using techniques such as CRISPR-Cas9 genome-editing.98 Fortunately, 
this technique has been used within the context of iPSCs for genome-editing and is routinely 
employed by the  hildren’s Hospital of Pennsylvania Human Pluripotent Stem  ell core.197 By 
precisely editing individual nucleotides within the Gq gene, one can induce specific candidate 
RGS-insensitive mutations that would be present at endogenous levels in the resultant platelets. 
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Finally, care should be taken when deciding appropriate methods to be used to assess the 
functional consequences of mutation in platelets. While generating platelets from iPSC-derived 
megakaryocytes is useful, yields are generally quite low. Thus, traditional methods, such as 
aggregometry, may not be viable without the use of large-scale culturing resources. However, 
single cell methods, such as flow cytometry, can overcome these challenges since relatively few 
cells are required for analysis. In the case of RGS-resistant mutations in Gq, measuring P-selectin 
exposure or IIb3 integrin activation would be a useful measurement of function, since these are 
largely Gq-driven processes. Furthermore, inhibitors of Gi signaling, such as Pertussis toxin, could 
be employed to minimize RGS:Gi effects as a confounding factor.198 A successful RGS-insensitive 
mutation in Gq would be expected to enhance the measurable responses outlined above, much 
as we have seen in our RGS knockout mouse models. An unsuccessful RGS-insensitive mutation 
would have no effect on response (neutral mutation) or a decreased response (likely due to 
disrupted PLC interactions). To further confirm the findings of these experiments, 
immunoprecipitation for WT or mutant Gq could be performed to measure effects on protein 
interactions. 
7.4 Function and RGS expression of RGS10 and RGS18 variant platelets 
 To improve our understanding of RGS-mediated platelet regulation in humans, we have 
identified 16 predicted loss-of-function variants in RGS10 and RGS18 within 101 individuals who 
have submitted samples to the Penn Medicine Biobank (see Chapter 5). Our goal is to determine 
how these mutations functionally impact platelet activation, RGS expression and platelet 
hemostatic potential. 
To determine impacts on platelet activation from patients, we will isolate platelets from 
whole blood and measure activation in response to GPCR-activating agonists via flow cytometry 
(as outlined in 7.2). We will also perform similar studies on controls that have been matched by 
age, gender, ethnicity and, if possible, use of medications expected to impact platelet activation 
(such as aspirin). 
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RGS expression levels will be determined using commercially available enzyme-linked 
immunosorbent assays (ELISA) for human RGS10 and RGS18. Use of standard curves with 
recombinant protein and the sensitivity of ELISA allows for the precise quantification of low levels 
of endogenous protein. While missense mutations would not necessarily be expected to alter 
expression levels, frameshifts and stopgains might and we predict that total RGS levels will 
negatively correlate with platelet activating potential. 
 Finally, since we do not yet have a way of assessing human platelet function in vivo, we 
will use CRISPR-Cas9 to induce candidate mutations in iPSCs (as outlined in 7.2) for the 
generation of RGS variant megakaryocytes. These megakaryocytes will then be injected into 
immunocompromised NOD-scid-IL-2Rγnull (NSG) mice199 that also express a von Willebrand factor 
variant (R1326H or VWFRH/RH) that can bind to human GPIb on human platelets, but not mouse 
GPIb.200,201 The double transgenic mice were developed by Morty Poncz at Children’s Hospital of 
Philadelphia using CRISPR/Cas9 to induce the VWF R1326H mutation in NSG mice.202 
Megakaryocytes produced in this manner lodge in the lungs after intravenous injection, releasing 
sufficient platelets to account for 5-10% of the circulating platelet pool in the mice.203 Even though 
human platelets are a minority in this model, they have a competitive advantage over the mouse 
platelets, which are unable to bind to VWFRH. Therefore, this method provides us with a novel way 
to study the in vivo hemostatic effects of mutations in human megakaryocytes and their derived 
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